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Begin and close your day with prayer so that you may have a 
peaceful night free from dreams & nightmares.  
To a good man, the whole world is good. Let us learn to treasure 
only good & reject the evil in everything.  
Speak the truth & remain non-violent at any cost. 
I am not against the wealth but the wealth that enslaves. 
 The real property a parent can transmit to all equally is his or her 
character & educational facilities. Have a clean companions-clean 
friends & clean books.  
Seven social sins: 
1. Politics without principles  
2. Wealth without work  
3. Pleasure without conscience  
4. Knowledge without character  
5. Commerce without morality 
 6. Science without humanity 
 7. Worship without sacrifice. 
-Mahatma Gandhi 
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PURPOSE OF STUDY 
   Drug substances most frequently are administered orally by means 
of solid dosage forms such as tablets and capsules. In a number of cases 
it has been shown that the drug substance’s solubility and other 
physiochemical characteristics have influenced its physiological availability 
from solid dosage formsEdward M et al., 2005. The chain of events that occur 
following administration of a solid dosage form such as a tablet or a 
capsule until its absorption into systemic circulation are depicted below. 
 
 
                                       
                                                                
 
 
   
 
  
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of steps involved in the 
absorption of solid dosage forms 
Solid dosage 
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 Solid drugs administered orally for systemic activity must dissolve in 
the gastrointestinal fluids prior to their absorption. Thus, the rate of 
dissolution of drugs in gastrointestinal fluids could influence the rate and 
extent of their absorption. The rate of dissolution of a solid is a function of 
its solubility in the dissolution medium; the latter could influence absorption 
of the relatively insoluble drugs. 
  
 The rate of dissolution can be altered via physical intervention. 
When the absorption of a drug is dissolution rate limited a more soluble 
and faster dissolving form may be utilized to improve the rate and extent of 
bioavailabilityDeodatt A et al., 1989.  
 
The loss of drug on first passage through the liver once it is 
absorbed into the systemic circulation is called the hepatic first pass effect. 
Drugs with poor bioavailability due to hepatic first pass effect can be 
administred through buccal and sublingual route to enable presystemic 
absorption and to bypass hepatic first pass effect, thus ensure better 
bioavailability. Sublingual and Buccal tablets are therefore ideal for potent, 
low dose drugs which are undergoing metabolism through hepatic first 
pass effectSalmon A. et al .,1989. 
 
When bioavailability is very low ex: - < 20 %, inter and intra subject 
variability in bioavailability are magnified and incomplete oral bioavailability 
can become a great concern. If bioavailability average 20%, for example 
then 80% of a dose is wasted. So maximizing bioavailability contributes to 
increasing the cost effectiveness of the drugNavnit H et al., 2008. 
  
 Several drugs have poor aqueous solubility to have a bearing on 
dissolution rate. The matter is of great concern when the solubility is less 
than 1-2 mg /ml in the pH range of 2-8. 
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 It is estimated that 50% of the population have problems swallowing 
the tablets. This leads to poor or even noncompliance with the treatment 
and thus has a negative effect on the efficiency of the treatmentSeager.H 1998. 
  
 Domperidone a prokinetic D2 receptor antagonist used in the 
treatment of nausea and vomiting as well as chemotherapy induced 
nausea and vomiting. It is practically insoluble in water and undergo 
extensive hepatic metabolism. According to the biopharmaceutical 
classification, it is a class II drug. The oral bioavailability of Domperidone is 
only 13 – 17 % due to poor aqueous solubility and hepatic first pass effect.   
 
So the main objective of the present study aims  
 
¾ To overcome the problem of poor bioavailability due poor aqueous 
 solubility  
¾ To overcome the problems of poor bioavailability due to hepatic first 
 pass effect. 
¾ To improve the palatability of the drug through formulation design. 
¾ To improve the cost effectiveness of the drug. 
¾ To draw a marketing strategy for the brand extension. 
 
The research work envisaged was  
1. Literature survey on solid dispersion methods and carriers for solid 
 dispersion. 
2. Preparation, characterization and evaluation of solid dispersions of 
 Domperidone with PEG 4000, PEG 6000 and PEG 8000. 
3. Formulation of non sugar muco adhesive sweetener (NSMAS). 
4. Formulation and evaluation of Orodispersible tablets of 
 Domperidone from selected solid dispersions of Domperidone. 
5. Stability studies on formulation. 
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INTRODUCTION 
 When the drug is administered in a solid dosage form such as 
tablet, capsule, or suspension it must be released from the dosage form 
and dissolved in the gastrointestinal fluids before it can be absorbed. 
Considering the principle of drug absorption by a passive transport 
mechanism 
   Jw = Pw × Cw 
   Where Jw – absorption rate 
    Pw – intestinal wall permeability 
    Cw – drug concentration at intestinal wall 
   
 Therefore maximum absorption rate is 
  Jw(max) = Pw × solubility 
 
 As permeability being constant, the solubility as well as the rate of 
dissolution is the rate limiting step for the absorptionWadke. D.A et al., 1989. 
 
 The dissolution rate limited absorption corresponds with the 
increase in dose. The concept of dose number was introduced to further 
understand the dose limitation in the rate and extent of absorption. 
 Dose number Do = ilitysoX
Dose
lub250
 
  (Note: 250 ml is considered as volume in the stomach) 
 
 Therefore a higher dose number which is generally associated with 
a high dose for a poorly soluble drug result in poor, incomplete, and 
variable absorption. Generally a dose number less than 10 is desired for 
higher absorption and bioavailabilityLoben B.R and Amidon GL, 2000. 
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BIOPHARMACEUTICS CLASSIFICATION SYSTEM 
 The BCS is a scientific framework which is included in the FDA 
guidelines for classifying drug substances based on their aqueous 
solubility and intestinal permeability. When combined with the in vitro 
dissolution characteristics of the drug product, the BCS has taken into 
account three major factors: solubility, intestinal permeability, and 
dissolution rate, all of which govern the rate and extent of oral drug 
absorption from immediate release solid dosage formsYu LX, et al, 2002. 
 
 The solubility classification of a drug in the BCS is based on the 
highest dose strength in an immediate release product. A drug substance 
is considered highly soluble when the highest strength is soluble in 250 ml 
or less of aqueous media over the pH range of 1.0 – 7.5; or else, the drug 
substance is considered poorly soluble. The volume estimate of 250 ml is 
derived from typical bio equivalence study protocols that prescribe 
administration of a drug product to human volunteers with a glass (about 8 
ounces) of water.  
 
 The permeability classification is based directly on the extent of 
intestinal absorption of a drug substance in humans or indirectly on the 
measurement of the rate of mass transfer across human intestinal 
membrane. Animal or in vitro model capable of predicting the extent of 
intestinal absorption in humans may be used as alternative, e.g., in situ rat 
perfusion models and in vitro epithelial cell culture models. A drug 
substance is considered highly permeable when the extent of intestinal 
absorption is determined to be 90% or higher. Otherwise, the drug 
substance is considered to be poorly permeable. 
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 An immediate release drug product is characterized as a rapid 
dissolution product when not less than 85% of the labeled amount of the 
drug substance dissolves within 30 minutes using USP Apparatus 1         
at 100 rpm or USP Apparatus II at 50 rpm in a volume of 900 ml or less of 
each of the following media: (i) acidic media, such as 0.1 N HCl or USP 
simulated intestinal fluid without enzymes. (ii) A pH 4.5 buffer and           
(iii) a pH 6.8 buffer or USP simulated intestinal fluid without enzymes. 
Otherwise, the drug product is considered to be a slow dissolution product. 
 
 The BCS classifies drugs into four categories depending on their 
solubility. 
Table 1:  Biopharmaceutics classification system 
Class Solubility Permeability 
I HIGH HIGH 
II LOW HIGH 
III HIGH LOW 
IV LOW LOW 
 
 Class I drugs are those which should have more than 90% 
absorption rate. Class II drugs are those with solubility too low to be 
consistent with the complete absorption, even though they are highly 
membrane permeable. 
 Class III is the mirror image of class II. These drugs have good 
solubility but were not capable of penetrating the gut wall quickly enough 
for the absorption to be complete. Class IV compounds have neither 
sufficient solubility nor permeability for absorption to be complete. 
Although they certainly do not possess optimal properties, some drugs in 
this category may still be absorbed well enough to permit oral 
administration. 
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 Typically dissolution rate limited drugs are BCS II and IV 
compounds. 
 
 Formulation plays a major role in determining the rate and extent of 
absorption of drug candidate which has reasonable membrane 
permeability and the absorption is dissolution rate limited. When water 
solubility is 1 µg/ml which is often the case for contemporary drug 
candidates, the bioavailability from conventional tablet formulation may be 
unacceptableLipinski.C.2000. 
 
 The choice of formulation is often critical for establishing a 
successful product for oral administration of a class II drug. Various 
successful approach to formulate poor water soluble crystalline drugs into 
oral dosage forms include particle size reduction, formation of salts, 
complexes or co crystals, amorphous formulations, lipid based 
formulations, and prodrug approaches. 
 
 The dissolution rate of crystalline drug from a solid dosage form can 
be increased by reducing the particle size and increasing the surface area 
for dissolution. During the dissolution process, a solid dosage form, i.e., a 
tablet or capsule will undergo the process of wetting, disintegration, 
deagglomeration, dislodgement, and dissolution. The size of the contact 
surface is critical for all the reactions and mass transfer. 
 
 According to the modified Noyes-Whitney equation   
 
 
 where dW/dt is the rate of dissolution, “A” is the surface area 
available for dissolution, “D” is the diffusion coefficient of the compound, 
“Cs” is the solubility of the compound in the dissolution medium, “C” is the 
dW 
dt 
DA(Cs - C) 
       L =
Chapter 2 Introduction 
 
 8
concentration of drug in the medium at time t and “L” is the thickness of 
the diffusion boundary layer adjacent to the surface of the dissolving 
compoundNoyes A.A and Whitney W.R, 1897, Nernst W, 1904.  
  
 Particle size reduction can increase the dissolution rate of a drug 
based on several aspects such as increased surface area, decreased 
diffusion layer, increased saturation solubility , and less sensitive to 
luminar hydrodynamics. 
 
 The bioavailability of a weak acid or weak base can be improved by 
the selection of an appropriate salt which is readily more soluble in the 
physiological fluids. 
  
 Co-crystal approach uses solvates, hydrates or eutectics to improve 
the solubility especially for non ionizable drugs. Careful selection of ligand 
or guest molecules can also increase solubility and or permeability. 
  
 Amorphous formulations include “solid dispersion and solid 
solutions” which can be formed using variety of technologies including 
solvent controlled precipitation, spray drying, hot melt extrusion, and fluid 
bed technology etc. 
  
 Prodrugs are also a common approach for improving the 
bioavailability.  
 
SOLID DISPERSIONS 
  Solid dispersion is defined as the dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state prepared by the 
melting (fusion), solvent or the melting-solvent method. 
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 The dispersion of a drug or drugs in a solid diluent or diluents by 
traditional mechanical mixing is not included in this category. The term   
co-precipitate (more accurately) co-evaporate has also been frequently 
used when a solid dispersion is prepared by a solvent method. 
 
ADVANTAGES OF SOLID DISPERSIONS 
¾ Solid dispersion of drugs in solid state is helpful in stabilizing 
 unstable drugs. 
¾ The PEGs may protect certain drug e.g. cardiac glycosides against 
the decomposition by saliva and allow buccal absorption. 
¾ Solid dispersions may be thermodynamically more active form of 
 drug and directly influence the diffusion and release rate. 
¾ An increased diffusion of steroid from the ointment was 
 obtained.e.g. Solid dispersion of prednisolone urea dispersion. 
¾ Solid dispersion technology can be used to solidify liquid drugs.e.g. 
 Clofibrate and benzyl benzoate.   
 
DISADVANTAGES OF SOLID DISPERSIONS 
¾ Tackiness and decomposition during preparation and formulation. 
¾ The oral administration of solid dispersions without concomitant 
reduction in dose may result in higher incidence of adverse effect. 
E.g. ulceration of indomethacin-PEG 6000 dispersion. 
¾ Difficulty in pulverization of solid dispersion. 
¾ Drug carrier incompatibility. 
¾ Poor flow and mixing properties. 
¾ Sifting of the solid dispersions, which are usually soft and tacky. 
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CLASSIFICATION OF SOLID DISPERSIONS 
1.  Simple eutectic mixtures 
 Solid eutectic mixtures are usually prepared by rapid cooling of a 
co-melt of two components in order to obtain a physical mixture of very 
fine crystals of the two components. When the preparation is dissolved in 
aqueous medium the carrier will dissolve rapidly, releasing very fine 
crystals of drug which offers large surface area thereby improvement in 
dissolution is effectedSekiguchi.K and Obi.N, 1961., Goldberg.A.H, et al., 1966. 
 
2.  Solid solutions 
 Solid solutions of a poor water soluble drug dissolved in a carrier 
with relatively good aqueous solubility are of particular interest as a means 
of improving oral bioavailability. In the case of solid solutions, the drug's 
particle size has been reduced to its absolute minimum viz. the molecular 
dimensions and the dissolution rate are determined by the dissolution rate 
of the carrier. By judicious selection of a carrier, the dissolution rate of the 
drug can be increased by up to several orders of magnitude. Solid 
solutions can be classified according to two methods. First, they can be 
classified according to their miscibility (continuous versus discontinuous 
solid solutions) or second, according to the way in which the solvate 
molecules are distributed in the solvendum (substitutional, interstitial or 
amorphous)Goldberg.A.H et al., 1965. 
 
2.2.1. CONTINUOUS AND DISCONTINUOUS SOLID SOLUTIONS 
2.2.1.1. Continuous solid solutions 
 In a continuous solid solution, the components are miscible in all 
proportions. Theoretically, this means that the bonding strength between 
the two components is stronger than the bonding strength between the 
molecules of each of the individual components. Solid solutions of this 
type have not been reported in the pharmaceutical literature to date.  
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2.2.1.2. Discontinuous solid solutions 
  In the case of discontinuous solid solutions, the solubility of each of 
the components in the other component is limited. 
 
2.2.2.  Substitutional crystalline, interstitial crystalline and 
 amorphous solid solutions 
 
2.2.2.1. Substitutional crystalline solid solutions 
 Classical solid solutions have a crystalline structure, in which the 
solute molecules can either substitute for solvent molecules in the crystal 
lattice or fit into the interstices between the solvent molecules. Substitution 
is only possible when the size of the solute molecules differs by less than 
15% or so from that of the solvent moleculesHume.R.W and Raynor.G.V, 1954. 
 
 2.2.2.2. Interstitial crystalline solid solutions 
 In interstitial solid solutions, the dissolved molecules occupy the 
interstitial spaces between the solvent molecules in the crystal lattice. As 
in the case of substitutional crystalline solid solutions, the relative 
molecular size is a crucial criterion for classifying the solid solution type. In 
the case of interstitial crystalline solid solutions, the solute molecules 
should have a molecular diameter that is no greater than 0.59 of the 
solvent molecule's molecular diameterReed-Hill R.E, 1964. Furthermore, the 
volume of the solute molecules should be less than 20% of the solvent.  
 
2.2.2.3. Amorphous solid solutions 
 In an amorphous solid solution, the solute molecules are dispersed 
molecularly but irregularly within the amorphous solvent. Using griseofulvin 
in citric acid, Chiou and Riegelman were the first to report the formation of 
an amorphous solid solution to improve a drug's dissolution properties. 
Other carriers that were used in early studies included urea and sugars 
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such as sucrose, dextrose and galactose. More recently, organic polymers 
such as polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and various 
cellulose derivatives have been utilized for this purposeChiou W.L and 
Riegelman.S, 1969
. 
 
SOLID DISPERSION TECHNIQUES 
1.  Melting or Fusion Method 
 The melting or fusion method was first proposed by  
Sekiguchi and Obi to prepare fast release solid dispersion dosage 
formsSekiguchi. K and Obi N, 1961. In this method the physical mixture of drug and 
the water soluble carrier is heated directly until it is melted. The melted 
mixture is then cooled and solidified in an ice bath under vigorous stirring. 
The final mass was crushed, pulverized and sieved. The dispersion can 
also be cooled through the process of spray congealing using spray drying 
equipment. The melted material is sprayed onto cold metal surfaces, 
which forms pellet of the dispersion. This does not require grinding and 
therefore no alteration of the crystal modification of the drug occurs. E.g. 
solid dispersion of sulphamethoxazole, acetaminophen, chloramphenicol, 
tolazamide, steroids. 
 
Advantages 
¾ Simplicity and economy. 
¾ This method also advantageous for compounds, which do not 
 undergo significant thermal degradation 
¾ Super saturation of a solute or drug in a system can often be 
obtained by quenching of the melt rapidly from high temperature. 
 
Disadvantages 
¾ The main disadvantage of the melt method includes thermal 
degradation, sublimation and polymeric transformation, which can 
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affect the physicochemical properties of the drug including its rate 
of dissolution. 
 
¾ The temperature at which the dispersion solidifies affects 
crystallization rate and may alter both the size of the crystal and 
hardness of the dispersion. This may result in tacky or glassy and 
unmanageable dispersions, which will require storage at elevated 
temperature to facilitate hardening.   
 
2.  Solvent Evaporation Method 
 This method involves dissolving the drug and carrier in a suitable 
organic solvent followed by evaporation of the solvent to form solid 
dispersion involves dissolving the drug and carrier in a suitable organic 
solvent followed by evaporation of the solvent to form solid dispersion. The 
mass was then stored in dessicator, pulverized and sieved. Removal is 
accomplished by various means. The most common approach is the 
application of reduced pressure at a fixed temperature to evaporate the 
organic solvent. Temperatures of 1250C for 25 minutes, 1150C for one 
hourChiou .W.I and Riegelman.S 1970, -50c and reduced pressure followed by drying 
for 12 hours in vacuum have been used Malone, M.H,et al.,1966.  
 
 Spray drying is another approach by which solvent removal can be 
accomplished and it is probably the fastest way of removing solvent Bloch, 
D.W, et al., 1983. The freeze drying technique is also employed to prepare solid 
dispersions by removal of aqueous solutionsSekikawa.H, et al., 1983. E.g. solid 
dispersion of β-carotene-PVP, griseofulvin-PVP and reserpine-deoxy 
cholic acid. 
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Advantages 
¾ The procedure is suitable for drugs that are thermo labile. 
¾ The thermal decomposition of drugs or carriers can be prevented 
because of the low temperature required for the evaporation of the 
organic solvents.  
¾ For aqueous system, frozen temperature can be used to evaporate 
the solvent, which can enhance the integrity of the drug. 
 
 Disadvantages 
¾ Difficulty in complete removal of solvent. 
¾ Finding a suitable solvent that will dissolve both the drug and carrier 
 is very difficult. 
¾ Plasticization of some polymers such as poly vinyl pyrrolidone has 
occurred with the use of some solvents. 
¾ It is important that the rate of evaporation of a solvent is controlled 
so as to control the particle size of the drug. This in turn will affect 
the rate of dissolution of the drug in the solid dispersion. 
 
3.  Fusion-Solvent Method 
 In the fusion solvent method, a carrier(s) is/are melted and the 
drug(s) is/are incorporated in the form of a solution. If the carrier is capable 
of holding a certain proportion of liquid yet maintaining its solid properties, 
and if the liquid is innocuous, the need for removal is eliminated. This 
method is particularly useful for drugs that have high melting points are 
that are thermo labile. The feasibility of the method has been 
demonstrated for spironolactone and griseofulvin dispersions in 
polyethylene glycol 6000 (PEG 6000)Chiou. W.I and Riegelman. S, 1971 . E.g. solid 
dispersion of clofibrate, methyl salicylate, benzyl benzoate. 
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MECHANISM OF INCREASED DISSOLUTION RATE BY SOLID 
DISPERSION SYSTEM 
¾ In the case of glass solutions, and amorphous dispersions, particle 
size is reduced to a minimum level. This can result in an enhanced 
dissolution rate due to both an increase in surface area and 
solubilization. 
¾ The carrier material as it dissolves may have a solubilization effect 
on the drug. 
¾ The carrier material may also have an enhancing effect on the 
wettability and dispersibility of the drug in the dissolution medium. 
Then should retard any agglomeration or aggregation of the 
particles, which can slow the dissolution process. 
¾ Formation of metastable dispersion that has a greater solubility 
would result in faster dissolution rates. 
 
CARRIERS USED FOR SOLID DISPERSION SYSTEMSChristian.L and 
Jennifer.D, 2000 
1. Polyethylene glycols (PEGs) 
2. Polyvinylpyrrolidone (PVP) 
3. Polyvinyl groups  
 ¾ Polyvinyl alcohol (PVA) 
 ¾ Crospovidone  
 ¾ Polyvinylpyrollidone-polyvinylacetate copolymer (PVP-PVA) 
4. Cellulose derivatives   
 ¾ Hydroxypropylmethylcellulose (HPMC) 
 ¾ Hydroxypropylcellulose (HPC)   
 ¾ Carboxymethylethylcellulose (CMEC) 
 ¾ Hydroxypropylmethylcellulose phthalate (HPMCP) 
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5. Polyacrylates and polymethacrylates 
 ¾ Eudragit E  
 ¾ Eudragit L 
6. Urea 
7. Sugar, polyols and their polymers 
 ¾ Dextrose  
 ¾ Sucrose  
8. Emulsifiers  
 ¾ Sodium Lauryl Sulphate  
 ¾ Tween 80 
9. Organic acids and their derivatives 
 ¾ Succinic acid  
 ¾ Citric acid 
10. Other carriers     
 ¾ Phospholipid        
 ¾ Pentaerythritol 
 
Table 2: Solid dispersion of therapeutic agents 
Drug Carriers Method Type of solid dispersion 
Effect of 
dissolution 
rate 
Allopurinol PVP S Not studied Increased 
Benzybenzoate PEG 6000 MS Not studied Increased 
Chloramphenicol Urea M Solid solution Increased 
Clofibrate PEG 6000 MS Not studied Increased 
Corticosteroids Sugars M Not studied Increased 
Diazepam PEG 4000 M solid solution Not studied 
Griseofulvin Succinic Acid M Solid solution Increased 
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PVP S Not studied Increased 
PEG- 
4000 MS Not studied Increased 
PEG- 
6000 M,S Not studied Increased 
PEG 2000 M Not studied Increased 
Citricacid M Glass suspension Increased 
Indomethacin PEG 6000 M Not studied Increased 
Methylsalicylate PEG 6000 S Not studied Increased 
Paracetamol Urea M Solid solution Increased 
Mannitol M Eutetic Increased  
Primidone Citric acid M Glass solution Increased 
Reserpine PVP S Not studied Increased 
Sulfathiazole Urea M Simple eutectic Not studied 
PEG- 
4000 S Not studied Increased 
PEG-6000 S Not studied Increased 
PEG4000 M,S Not studied Increased 
PEG-2000 M,S Mono acetic Not studied 
PVP S Not studied Increased 
PEG-8000 M,S Not studied Increased 
PVP S Not studied Increased 
PEG-6000 S Not studied Increased 
Tobultamide 
PEG-4000 M Not studied Increased 
o  *M-Melting Method S- Solvent Method MS- Melting solvent method 
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ORODISPERSIBLE TABLETS 
 Orodispersible tablets (ODTs) are uncoated tablets intended to be 
placed in the mouth where they disperse rapidly before being swallowed 
without the aid of additional water. These tablets disintegrate within 3 
minutesEuropean pharmacopoeia 1996. Orodispersible tablets are otherwise known 
as Orally Disintegrating Tablets, Rapidly Disintegrating Tablets and Fast 
Dissolving Tablets. 
 
 For a tablet to be classified as an ODT tablet the disintegration time 
should be sufficiently rapid for the patient to not feel the need or 
compulsion to chew. One of the greatest benefits of ODTs over 
conventional tablets is enhanced patient compliance and acceptance 
related to both feasibility and convenience of dosage administrationCheu P et 
al., 2004
. As many as 50 % of the population have difficulty swallowing intact 
tablets and hard gelatin capsulesSeager.H, 1998.These include pediatric and 
geriatric populations who have difficulty in swallowing large tablets. 
 
 Patients who are bedridden, mentally retarded, uncooperative, 
nauseous, and those suffering from nervous or anatomical disorders of the 
larynx or esophagus, or on reduced liquid intake diets also cannot swallow 
conventional tabletsShen Y et al., 2007. 
 
 The bioavailability between the Orodispersible tablets and 
conventional tablets differ considerably. With conventional tablets the 
contact time between the drug substance and Oromucosal tissues are 
minimal and most of the absorption takes place in the stomach and or the 
intestines. However, drug released from ODTs also has the opportunity to 
be absorbed by local Oromucosal tissues and Pregastric regions, 
especially if the residence time in the mouth is prolonged. Oromucosal and 
pregastric absorption can potentially produce a rapid response, and partial 
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avoidane of first pass effects and gastrointestinal irritation  Freudenreich.O, 2003. 
It is apparent that the formulation of orally disintegrating tablets can 
significantly change the bioavailability of some drugs. 
 
Advantages of ODT    
¾ Best for patients with esophageal problems and have difficulties of 
 deglutition tablets. 
¾ High drug loading is possible 
¾ Leave minimum residue in the mouth after oral administration 
¾ Guarantee a rapid onset of action when required 
¾ Patient compliance due to pleasant mouth feel 
¾ Cost effectiveKundu.S and Sahoo.P.K, 2008. 
 
Disadvantages of ODT    
¾ ODTs may not be beneficial for those who with very dry mouth. 
¾ Masking the bitter tasting drugs post formidable challenges in 
 formulating as ODTs. 
¾ It is difficult to achieve sufficient strength of ODTs to withstand the 
 rigors of the manufacturing process and handling. 
¾ Coatings of active pharmaceutical ingredients are often needed for 
 taste masking of bitter drugsKundu.S and Sahoo.P.K, 2008. 
 
Technologies for manufacturing ODTs 
 Technologies for manufacturing ODTs include the freeze drying 
method, cotton candy technology, and compressed tablets. The Zydis® 
(R.P.Scherer, Troy,Michigan,U.S.A) technology is used to make freeze 
dried wafers which dissolve nearly instantly in the mouth and leave no 
gritty residue. Compressed tablets usually dissolve slower than the freeze 
dried wafers and may leave a gritty mouth feel if insoluble excipients are 
used. However the compressed tablets technology is less expensive and 
may be more suited for loading large amount of active ingrdients. 
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1. Freeze drying technology 
 Freeze drying or lyophilization technology was introduced by Zydis 
delivery system developed by R.P.Scherer. It is a mixture of gelatin, 
sugar(s), active ingredients, and other components poured into the 
depression of a blister pack. Water is sublimed away during lyophilization 
leaving a highly porous, relatively soft sold. The resulting wafers dissolve 
or disperse on the tongue rapidly in about three to five seconds. Some of 
the limitations of the freeze dried wafers are drug solubility and a drug 
loading limitation of about 60 mg for water soluble drugsSeager H, 1998.The 
wafers are also moisture sensitive and very fragile, requiring special 
packaging. 
 
2. Cotton candy technology 
 Cotton candy process also known as the candy-floss process, 
which involves centrifugation to produce floss like crystalline structure. In 
this technology, the matrix is formed from saccharides or polysaccharides 
processed into an amorphous floss through a shear foam process. The 
matrix is crushed and milled to make a flow able, compactable, and highly 
soluble filler. Because of the formation of porous three dimensional 
structures with the active ingredients encased in the pores, the resulting 
surface area is high. Therefore, dispersion and dissolution occur quickly 
when the product is placed in the mouthYoo.J, et al., 1998. 
 
3. Tablet compression technology 
 ODTs can be formed by either direct compression, wet granulation 
or by a wet compression method. In the wet compression method, water is 
added to a power blend and the mixture is kneaded until a homogenous 
wet power mass is formed. The mass is then extruded through a sieve. 
Wet granules are then compressed into tablets. The wet compression 
method may not be suitable for active materials that are physically or 
chemically unstable in the presence of water. 
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 The direct or dry compression method is generally preferred 
because it is simpler, easier to automate, and avoids direct contact of 
water with the active material. As with wet compression, it is often capable 
of producing ODTs with sufficient physical robustness to allow physical 
handling and packagingRowe.R and Roberts.R, 1998. 
 
4. Moulding 
 Moulding is done by two methods compression moulding and heat 
moulding. Compression moulding tablets are prepared compressing a 
powered mixture previously moistened with solvent (usually ethanol or 
water) into mould plates to form a wetted mass. In heat moulding the drug 
is dissolved or dispersed in a molten matrix. Now vacuum lyophilization is 
a new technique in which evaporation of solvent from a drug solution or 
suspension is done at standard pressure. Tablets produced by moulding 
are solid dispersions, having advantage of very rapid dissolution (5 to 15 
sec) and can load high dose. The major disadvantages are high cost of 
production, weak mechanical strength and possible limitation in 
stabilityDobetti.L ,2001. 
 
Superdisintegrants  
 Disintegrants are very important component of compressed ODTs 
because they often are primarily responsible for the fast disintegration in 
the mouth. ODTs can contain either superdisintegant or an effervescent 
system as a disintegrating agent. An effervescent system (e.g., sodium 
bicarbonate and citric acid combination) generally provides a highly 
effective disintegrating system. The release of carbon dioxide when the 
effervescent agents come in contact with water helps to collapse the tablet 
matrix. To minimize any possible unpleasantness owing to a fizzing 
sensation in the mouth, formulators may choose to minimize the level of 
effervescent ingredients used in the formulation. 
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 In conventional tablets super disintegrants, such as croscarmellose 
sodium, sodium starch glycolate, and crospovidone are generally effective 
at lower concentrations than the traditional disintegrant, starch, and may 
be used at 2-5%. Although high levels of superdisintegrants do not 
necessarily produce faster disintegration in conventional tablets, as much 
as 15% of superdisintegrants may be beneficial in ODTs.  
 
 Superdisintegrants are strongly hygroscopic materials that aid in 
wicking water from the saliva into the internal structure of the tablets. An 
advantage of using superdisintegrants over the effervescent system is that 
they are less vulnerable than the latter to the detrimental effect of 
moisture. Nevertheless, the hygroscopicity of superdisintegrant is such 
that both their functionality and tablet stability can be compromised by 
excessive exposure to high humidity. Of the three widely used 
superdisintegrants, croscarmellose sodium seems to be less affected by 
high moisture level in regards to functionality,but all disintegrants are 
vulnerable to the detrimental effect of humidity. 
 
 High levels of disintegrants ,high level of soluble fillers, heat 
generated from the tablet presses, and atmospheric moisture can easily 
induce or promote stickiness at the punches which may pose a challenge 
to the formulation scientistHahm HA 2002. 
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VOMITING 
 Vomiting is a complex process that consists of a pre-ejection phase 
(gastric relaxation and retroperistalsis), retching (rhythmic action of 
respiratory muscles preceding vomiting and consisting of contraction of 
abdominal and intercostal muscles and diaphragm against a closed 
glottis), and ejection (intense contraction of the abdominal muscles and 
relaxation of the upper esophageal sphincter). This is accompanied by 
multiple autonomic phenomena including salivation, shivering, and 
vasomotor changes. During prolonged episodes, marked behavioral 
changes including lethargy, depression, and withdrawal may occur.  
 
 The process appears to be coordinated by a central emesis center 
in the lateral reticular formation of the mid-brainstem adjacent to both the 
chemoreceptor trigger zone (CTZ) in the area postrema (AP) at the bottom 
of the fourth ventricle and the solitary tract nucleus (STN) of the vagus 
nerve. The lack of a blood-brain barrier allows the CTZ to monitor blood 
and cerebrospinal fluid constantly for toxic substances and to relay 
information to the emesis center to trigger nausea and vomiting. The 
emesis center also receives information from the gut, principally by the 
vagus nerve (via the STN) but also by splanchnic afferents via the spinal 
cord.  
 
 Two other important inputs to the emesis center come from the 
cerebral cortex (particularly in anticipatory nausea or vomiting) and the 
vestibular apparatus (in motion sickness). In turn, the center sends out 
efferents to the nuclei responsible for respiratory, salivary, and vasomotor 
activity, as well as to striated and smooth muscle involved in the act of 
vomiting. The CTZ has high concentrations of receptors for serotonin (5-
HT3), dopamine (D2), and opioids, while the STN is rich in receptors for 
enkephalin, histamine, and ACh, and also contains 5-HT3 receptors. A 
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variety of these neurotransmitters are involved in nausea and vomiting and 
an understanding of their nature has allowed a rational approach to the 
pharmacological treatment of nausea and vomitingPankaj.J.P.2006. 
 
CYTOTOXIC INDUCED NAUSEA AND VOMITING (CINV) 
 Nausea and vomiting are well recognized in many diverse clinical 
situations, suggesting that no single mechanism is likely to be responsible 
for their production. Cytotoxic drugs used in the treatment of a range of 
malignancies, may produce severe gastrointestinal toxicity. This may lead 
to a refusal of curative therapy or to a decline in palliative benefits offered 
by cytotoxic treatment. The exact mechanism of chemotherapy induced 
nausea and emesis are poorly understood; however, an appreciation of 
the vomiting process remains essential to a rational approach to the 
therapeutics of anti-emesis. Chemotherapy induced vomiting is thought to 
act via the CTZ/AP. Despite the identification of several important 
neurotransmitters, no single anti-emetic agents have been able to 
counteract chemotherapy induced emesis with universal success. This 
suggests that complex patterns of chemoreception and neurotransmission 
are occurring within the AP-tractus solitaries-vomiting centre axis. 
 
 The most commonly used anti-emetics are those which block 
dopamine, histamine or acetylcholine receptors and selective receptor 
antagonism has formed the basis of the approach to anti-emetic 
therapeuticsEdwards C M,1988. 
 
 Domperidone is a benzimidazole derivative which is a peripheral 
dopamine receptor blocker promoting gastric motility. It is thought to offer 
advantages over conventional anti-emetics since it does not cross the 
blood brain barrier and therefore produce a low incidence of CNS side 
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effects including sedation and extrapyramidal reactions. Domperidone, like 
metoclopramide also acts at the CTZ,D2 blockade. Domperidone has been 
shown to be superior to placebo and either superior or equivalent to 
metoclopramide Harris Al, and cantwell, 1984. 
 
ANTIEMETICS CLASSIFICATION 
 Antiemetics generally are classified according to the predominant 
receptor on which they are proposed to act Edwards C M, 1988, Rang H.P., et al, 2003. 
1. Anti cholinergics 
  Hyoscine 
  Dicylomine 
2.  H1 antagonists 
  Promethazine 
  Diphenhydramine 
  Dimenhydrinate 
  Cyclizine 
  Meclizine 
  Cinnarizine 
3.  Dopamine receptor antagonists 
  Chlorpromazine 
  Prochlorperazine 
  Trifluoperazine 
  Thiethylperazine 
  Haloperidol 
  Droperidol 
4. Prokinetic drugs 
  Metaclopramide 
  Domperidone 
  Cisapride 
  Mosapride 
 
5.  5HT3 antagonist 
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  Ondansetron 
  Granisetron 
  Tropisetron  
  Dolasetron 
  Palonosetron 
6.  Adjuvant antiemetics 
a) Glucocorticoids 
  Dexamethasone 
  Methylprednisolone 
b)  Benzodiazepines 
  Lorazepam 
  Alprazolam 
c) Cannbinoids 
  Dronabinol 
  Nabilone 
d) NSAID’s 
e) Substance “p” receptor antagonist 
  Cisplatin 
f) Other agents 
  Benzoquimanide 
  Trimethobenzamide 
  Alizapride 
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DRUG PROFILE 
DOMPERIDONE 
 Domperidone is a D2 receptor antagonist that acts in the CTZ. It has 
a peripheral prokinetic action to increase the motility of the esophagus, 
stomach and intestine. Domperidone does not penetrate the blood brain 
barrier to any extent and, it is free from central side effectsBP 1996. 
 
Chemical name 
 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl) propyl] piperidin-4-yl]-
1H-benzimidazol-2-one 
 
Empirical formula 
 C22H24ClN5O2 
Chemical Structure 
 
Characteristics 
 White or almost white powder. Practically insoluble in water, soluble 
in dimethylformamide, slightly soluble in alcohol and in methanol. Melting 
point is 244°-248°C. 
 
Pharmacology 
 Domperidone has peripheral dopamine receptor blocking 
properties, it increases esophageal peristalsis and increases lower 
esophageal sphincter pressure, increases gastric motility and peristalsis, 
and enhances gastro duodenal coordination, therefore facilitating gastric 
emptying and decreasing small bowel transit time. 
N 
N 
H 
O
N
N
N
H
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Pharmacokinetics 
 Oral bioavailability 13-17 % 
 Protein binding 91- 93% 
 Onset of action 30 min -60 min 
 Cmax - 90 min 
 Metabolism-hepatic via N-dealkylation(CYP3A4) and hydroxylation. 
 Half life elimination: 7- 9 hours 
 Excretion: feces (66%): urine (31%). www.drugbank .ca 
 
Indications 
 Symptomatic management of upper gastro intestinal motility 
disorders associated with chronic and sub acute gastritis and diabetic 
gastroparesis; prevention of GI symptoms associated with use of 
dopamine agonist anti-Parkinson agents. Domperidone is also used in 
chemotherapy induced nausea and vomitingEdwards C M, 1988.  
 
Pregnancy implications 
 Animal studies have not shown drug related teratogenic or primary 
embryo toxic effects on animal fetuses; however comparative studies have 
not been done in humans. Use only when benefit outweighs potential risk 
in a pregnant woman.  
 
Lactation 
 Enters breast milk, not recommended. 
 
Contraindications 
 Hypersensitivity to Domperidone or any component of the 
formulation; patients with gastro intestinal hemorrhage, mechanical 
obstruction, or perforation; patients with prolactin releasing pituitary tumor. 
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Drug interactions 
 Cytochrome P450 effect: substrate of CYP3A4 (minor) 
 Increased effect/toxicity: Domperidone may increase the rate of 
absorption of drugs from the stomach, absorption of sustained release or 
enteric coated tablets may be altered. QTc prolonging drugs should be 
used with caution in combination with Domperidone, includes type Ia and 
type III anti arrhythmics, some fluoroquinolones and selected 
antipsychotics (thioridazine,mesoridazine) . 
 
 Decreased effect: anticholinergics decrease the effect of 
Domperidone. Domperidone may slow the rate of absorption of drugs from 
the gastrointestinal tract (sustained release or enteric coated 
formulations). 
 
Adverse drug reactions 
 Adverse drug reactions  ranges between 1%  and 10 %. 
 
Central nervous system:  
 Head ache/ migraine (1%); does not cross blood brain barrier; fewer 
CNS effects compared to metoclopramide. 
 
Gastrointestinal: xerostomia (2%) 
 Less than 1% ; dizziness, dysuria, edema, extra pyramidal 
symptoms(EPS), rarely galactorrhea, gynecomastia, hot flashes, 
increased serum prolactin, insomnia, irritability, nervousness, mastalgia, 
menstrual irregularities, pruritus, rash. 
Dose and Administration 
Adults 
 GI motility disorders: 10 mg 3 – 4 times/day, 15 – 20 minutes before 
meals; 
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 Severe resistant cases 20 mg 3-4 tomes/day, 15 – 30 minutes 
before meals. 
 Maximum 80 mg/day. 
 Nausea/vomiting: 20 mg 3 – 4 times/day 
 Dosage adjustment in renal impairment: decrease dose to 10 – 20 
mg 1 – 2 times/day. 
 
Children: 
 Less than 2 yr and less than 35 kg: 10 – 20 mg 3- 4 times /day. 
 
Stability 
 Store at room temperature of 15o c to 30o c (59o F to 86oF); protect 
from light and moisture. 
 
Warnings/precautions 
 Domperidone may increase prolactin levels (dose dependent 
response). Elevated prolactin may be asymptomatic(clinical consequence 
of chronically elevated prolactin is unknown) or may present 
symptomatically as galactorrhea, gynecomastia, amonorrhea, or 
impotence (reversible upon decreasing dose or discontinuing drug). 
 
 QTc prolongation , life threatening tachy arrhythmias, and cardiac 
arrest have been reported after Domperidone use; there adverse effects 
may be precipitated in hypokalemic patients. Use with caution in patients 
with hepatic impairement. 
 
 Use caution when administering Domperidone to patients with a 
personal or family history of breast cancer, use with caution in patients on 
MAO inhibitors. 
 Safety and efficacy have not been established in pediatric patients. 
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Over dose / toxicology 
 Symptoms of over dose include CNS effects such as drowsiness, 
disorientation, and extra pyramidal reaction. And cardiovascular effects 
such as arrhythmias and hypertension. 
 
 Treatment is supportive. Extrapyramidal effects may be controlled 
by anticholinergic agents (benztropine 1- 2 mg I.M/I.V) or antihistaminics 
with high anticholinergic activity (diphenhydramine 25- 50 mg I.M/I.V) 
 
Interaction with food 
 Delayed absorption but higher bioavailability due to reduced first 
pass metabolism in gut wall. 
 
Additional information 
  The FDA has issued a warning concerning the off label use 
of Domperidone to increase milk production in breast feeding woman. 
Domperidone is not available for any use in the United States and does 
not have approval for this indication in other countries. However, the FDA 
is aware that woman is obtaining Domperidone from U.S compounding 
pharmacies and foreign sources for this purpose. The FDA note that there 
is health risks associated with the use of this product that is why it has 
been removed from marketingGoodman and Gilman’s, 2001.  
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POLYMER PROFILE 
Polyethylene Glycol Raymond C R, 2003 
1. Non proprietary names 
            BP :  Macrogols 
 JP :  Macrogol 4000 
        Macrogol 6000 
     Macrogol 8000 
 PhEur :  Macrogola 
 USP/NF:  Polyethylene glycol 
 
2.  Synonyms 
 Carbowax; carbowax sentry; lipoxol; lutrol E; PEG; Pluriol E; 
Polyoxyethylene glycol.  
 
3.  Chemical name 
 α-Hydro-ω-hydroxypoly(oxy-1,2-ethanediyl) 
 
4.  Empirical formula 
 HOCH2(CH2OCH2)mCH2OH where m represents the average 
number of Oxyethylene groups. 
 The average molecular weights of polyethylene glycols are as 
follows. Note that the number that follows PEG indicates the average 
molecular weight of the polymer. 
Molecular weight of polyethylene glycol polymers. 
Grade Average molecular weight 
PEG 4000 3000–4800 
PEG 4600 4400–4800 
PEG 8000 7000–9000 
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5.  Structural formula: 
 
 
6. Functional category 
 Ointment base; plasticizer; solvent; suppository base; tablet and 
capsule lubricant. 
 
7.  Description 
 The USP/NF 23 describes polyethylene glycol as being an addition 
polymer of ethylene oxide and water. Polyethylene glycol grades 200–600 
are liquids; grades 1000 and above are solids at ambient temperatures. 
 
 Liquid grades (PEG 200–600) occur as clear, colorless or slightly 
yellow-colored, viscous liquids. They have a slight but characteristic odor 
and a bitter, slightly burning taste. PEG 600 can occur as a solid at 
ambient temperatures. 
 
 Solid grades (PEG>1000) are white or off-white in color, and range 
in consistency from pastes to waxy flakes. They have a faint, sweet odor. 
Grades of PEG 6000 and above are available as free-flowing milled 
powders. 
 
8.  Typical properties 
Density 
¾ 1.11–1.14 g/cm3 at 25°C for liquid PEGs; 
¾ 1.15–1.21 g/cm3 at 25°C for solid PEGs. 
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Melting point 
¾ 50–58°C for PEG 4000; 
¾ 55–63°C for PEG 6000; 
¾ 60–63°C for PEG 8000; 
Moisture content 
   Liquid polyethylene glycols are very hygroscopic, although 
hygroscopicity decreases with increasing molecular weight. Solid grades 
e.g. PEG 4000 and above, are not hygroscopic. 
 
Surface tension 
   Approximately 44 mN/m (44 dynes/cm) for liquid polyethylene 
glycols; approximately 55 mN/m (55 dynes/cm) for 10% w/v aqueous 
solution of solid polyethylene glycol. 
 
Viscosity (kinematic) 
Specifications from PhEur 2005 
Type of 
PEG 
Density 
(g/cm3) 
Freezing 
point (°C) 
Hydroxyl 
value 
Viscosity 
(dynamic) 
[mPa s (cP)] 
Viscosity 
(kinematic) 
[mm2/s (cSt)] 
4000 1.080 53–59 25–32 110–170 102–158 
6000 1.080 55–61 16–22 200–270 185–250 
8000 1.080 55–62 12–16 260–510 240–472 
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Viscosity of selected polyethylene glycols at 25°C and 99°C. 
Viscosity [mm2/s (cSt)] 
Type of PEG 
25°C 99°C 
PEG 4000 solid 180 — 
PEG 6000 solid 580 — 
PEG 20000 solid 6 900 — 
 
8.  Solubility 
   All grades of polyethylene glycol are soluble in water and miscible 
in all proportions with other polyethylene glycols (after melting, if 
necessary). Aqueous solutions of higher-molecular-weight grades may 
form gels. Liquid polyethylene glycols are soluble in acetone, alcohols, 
benzene, glycerin, and glycols. Solid polyethylene glycols are soluble in 
acetone, dichloromethane, ethanol (95%), and methanol; they are slightly 
soluble in aliphatic hydrocarbons and ether, but insoluble in fats, fixed oils, 
and mineral oil. 
 
9.  Stability and storage conditions 
 Polyethylene glycols are chemically stable in air and in solution, 
although grades with a molecular weight less than 2000 are hygroscopic. 
Polyethylene glycols do not support microbial growth, and they do not 
become rancid. 
 Polyethylene glycols and aqueous polyethylene glycol solutions can 
be sterilized by autoclaving, filtration, or gamma irradiation. Sterilization of 
solid grades by dry heat at 150°C for 1 hour may induce oxidation, 
darkening, and the formation of acidic degradation products. Ideally, 
sterilization should be carried out in an inert atmosphere. Oxidation of 
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polyethylene glycols may also be inhibited by the inclusion of a suitable 
antioxidant. 
 If heated tanks are used to maintain normally solid polyethylene 
glycols in a molten state, care must be taken to avoid contamination with 
iron, which can lead to discoloration. The temperature must be kept to the 
minimum necessary to ensure fluidity; oxidation may occur if polyethylene 
glycols are exposed for long periods to temperatures exceeding 50°C. 
However, storage under nitrogen reduces the possibility of oxidation. 
 Polyethylene glycols should be stored in well-closed containers in a 
cool, dry place. Stainless steel, aluminum, glass, or lined steel containers 
are preferred for the storage of liquid grades. 
 
10.  Safety 
 Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant 
materials.  
 
 Adverse reactions to polyethylene glycols have been reported, the 
greatest toxicity being with glycols of low molecular weight. However, the 
toxicity of glycols is relatively low. 
 
 Polyethylene glycols administered topically may cause stinging, 
especially when applied to mucous membranes. Hypersensitivity reactions 
to polyethylene glycols applied topically have also been reported, including 
urticaria and delayed allergic reactions.  
  
 The most serious adverse effects associated with polyethylene 
glycols are hyperosmolarity, metabolic acidosis, and renal failure following 
the topical use of polyethylene glycols in burn patients. Topical 
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preparations containing polyethylene glycols should therefore be used 
cautiously in patients with renal failure, extensive burns, or open wounds. 
Oral administration of large quantities of polyethylene glycols can have a 
laxative effect. Therapeutically, up to 4 L of an aqueous mixture of 
electrolytes and high-molecular-weight polyethylene glycol is consumed by 
patients undergoing bowel cleansing.  
  
 Liquid polyethylene glycols may be absorbed when taken orally, but 
the higher-molecular-weight polyethylene glycols are not significantly 
absorbed from the gastrointestinal tract. Absorbed polyethylene glycol is 
excreted largely unchanged in the urine, although polyethylene glycols of 
low molecular weight may be partially metabolized. 
  
 The WHO has set an estimated acceptable daily intake of 
polyethylene glycols at up to 10 mg/kg body-weight. 
  
 In parenteral products, the maximum recommended concentration 
of PEG 300 is approximately 30% v/v as hemolytic effects have been 
observed at concentrations greater than about 40% v/v. 
 
11.  Application in pharmaceutical formulation or technology 
 Polyethylene glycols (PEGs) are widely used in a variety of 
pharmaceutical formulations including parenteral, topical, ophthalmic, oral, 
and rectal preparations. It has been used experimentally in biodegradable 
polymeric matrices used in controlled-release systems.  
 
 Polyethylene glycols are used as ointment bases to the skin as they 
do not readily penetrate the skin, nonirritant and are water soluble. Solid 
grades are generally employed in topical ointments, with the consistency 
of the base being adjusted by the addition of liquid grades. 
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 Mixtures of polyethylene glycols can be used as suppository bases, 
for which they have many advantages over fats. 
 
 Aqueous polyethylene glycol solutions can be used either as 
suspending agents or to adjust the viscosity and consistency of other 
suspending vehicles. When used in conjunction with other emulsifiers, 
polyethylene glycols can act as emulsion stabilizers. Liquid polyethylene 
glycols are used as water-miscible solvents for the contents of soft gelatin 
capsules.In concentrations up to approximately 30% v/v, PEG 300 and 
PEG 400 have been used as the vehicle for parenteral dosage forms. 
  
 In solid-dosage formulations, higher-molecular-weight polyethylene 
glycols can enhance the effectiveness of tablet binders and impart 
plasticity to granules. However, they have only limited binding action when 
used alone, and can prolong disintegration if present in concentrations 
greater than 5% w/w. When used for thermoplastic granulations, a mixture 
of the powdered constituents with 10–15% w/w PEG 6000 is heated to  
70–75°C. The mass becomes pastelike and forms granules if stirred while 
cooling. This technique is useful for the preparation of dosage forms such 
as lozenges when prolonged disintegration is required. 
 
 Polyethylene glycols can also be used to enhance the aqueous 
solubility or dissolution characteristics of poorly soluble compounds by 
making solid dispersions with an appropriate polyethylene glycol. Animal 
studies have also been performed using polyethylene glycols as solvents 
for steroids in osmotic pumps. 
 
 In film coatings, solid grades of polyethylene glycol can be used 
alone for the film-coating of tablets or can be useful as hydrophilic 
polishing materials.Polyethylene glycols are useful as plasticizers in 
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microencapsulated products to avoid rupture of the coating film when the 
microcapsules are compressed into tablets. 
 
 Polyethylene glycol grades with molecular weights of 6000 and 
above can be used as lubricants, particularly for soluble tablets. The 
lubricant action is not as good as that of magnesium stearate and 
stickiness may develop if the material becomes too warm during 
compression. An antiadherent effect is also exerted, again subject to the 
avoidance of overheating. 
 Polyethylene glycols have been used in the preparation of urethane 
hydrogels, which are used as controlled-release agents. It has also been 
used in insulin-loaded microparticles for the oral delivery of insulin; it has 
been used in inhalation preparations to improve aerosolization; 
polyethylene glycol nanoparticles have been used to improve the oral 
bioavailability of cyclosporine; it has been used in self-assembled 
polymeric nanoparticles as a drug carrier; and copolymer networks of 
polyethylene glycol grafted with poly(methacrylic acid) have been used as 
bioadhesive controlled drug delivery formulations.  
 
12.  Regulatory status 
    Included in the FDA Inactive Ingredients Guide (dental 
preparations; IM and IV injections; ophthalmic preparations; oral capsules, 
solutions, syrups, and tablets; rectal, topical, and vaginal preparations). 
Included in nonparenteral medicines licensed in the UK. Included in the 
Canadian List of Acceptable Non-medicinal Ingredients 
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REVIEW OF LITERATURE 
¾  Robert G et al., (1990) have patented fast dissolving dosage forms 
of Chlorpheniramine Maleate which disintegrate within ten seconds. 
Water soluble or water dispersible carrier materials were used in 
the group consisting essentially of mannitol in admixture with a 
natural gum, preferably acacia, guar gum, xanthan gum and 
tragacanth gum, pectin, algin, agar, carrageenan and gum Arabic. 
The mannitol constituted at least about 10 % by weight of the final 
dosing suspension and no more than about 15% by weight.  
¾ N Jaymin et al., (1995) have attempted to enhance the aqueous 
solubility and dissolution rate of Etoposide by solid state 
modifications using PEG of different molecular weights in various 
ratios. The co-precipitate of Etoposide with PEG 8000(1:10, PEG 
weight fraction of 0.91) increased its solubility 2 fold and dissolution 
rate 42 fold. The co-precipitate with PEGs (PEG 1500, PEG 3400 
and PEG 6000) also increased Etoposide dissolution rate to great 
extent. 
¾  Franco et al., (2001) have studied dissolution properties and 
anticonvulsant activity of phenytoin-polyethylene glycol 6000 and 
polyvinylpyrollidone K-30 solid dispersions with different drug to 
carrier ratios were prepared by the solvent method. Among the 
various ratios, drug solubility and dissolution rate are improved by 
these formulations, particularly with SDPEG 1/20 and SDPVP 1/20 
systems. Storage was found to influence the stability of the solid 
dispersions. . By maximal electroshock test, it was found that the 
intraperitoneal administration in mice of the SDPEG 1/20 and 
SDPVP 1/20 systems exhibited anticonvulsant activity similar to 
diphenylhydantoin sodium salt. 
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¾ Shenoy et al., (2003) prepared and optimized fast dissolving 
tablets of Diclofenac sodium by direct compression method using 
superdisintegrants such as cross linked carboxymethylcellulose, 
sodium starch glycolate and cross linked povidone in different 
concentrations. Tablets containing cross linked 
carboxymethylcellulose showed better disintegrating character 
along with rapid release (90% drug release in 10 min). 
¾ Yamashita.k et al., (2003) have established new preparation 
method for solid dispersion formulation of Tacrolimus using three 
different carriers like polyethylene glycol 6000 (PEG 6000), 
polyvinylpyrollidone (PVP) and hydroxypropylmethylcellulose 
(HPMC) were prepared by the conventional solvent method, in 
which Tacrolimus and the carrier was completely dissolved in the 
mixture of Dichloromethane and Ethanol. In new method solid 
dispersion of Tacrolimus was prepared without using 
dichloromethane as a solvent. The in vivo oral absorption study in 
dogs showed that bioavailability of Tacrolimus from SD with HPMC 
was remarkably improved compared with the crystalline powder. It 
was clarified that HPMC is the most appropriate carrier for SD of 
Tacrolimus. The physicochemical properties of SD with HPMC 
prepared by the new method were the same as those of SD 
prepared by the conventional solvent method. They concluded the 
pharmacokinetic parameters after oral administration in monkeys 
showed no significant difference (P >0.01) between solid dispersion 
s with HPMC prepared by the two methods. 
¾ Faham et al., (2004) have patented Orodispersible tablets 
containing Fexofenadine a synthetic antiallergic using mennitol as 
diluent(50 – 90 % w/w) and crospovidone as disintegrant(2-15 % 
w/w) and othe exipients like precipitated silica, sweetener and 
flavors. 
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¾ Kashappa et al., (2004) have examined the enhancement of 
solubility of Valdecoxib using a series of hydrophilic carriers 
(mannitol,PEG 4000, PEG 6000, PEG 8000 and urea), surfactants 
(tween 20, tween 80 and sodium lauryl sulphate) and cosolvents 
(ethanol, methanol and glycol) at 370 c.  The solubility of Valdecoxib 
could be enhanced significantly using PEG 4000 as a carrier, 
ethanol as cosolvent and SLS as a surfactant.  
¾ Patel DM et al., (2004) have demonstrated the use of factorial 
design in the formulation of Orodispersible tablets of Rofecoxib. 
Preliminary screening of three superdisintegrants namely sodium 
starch glycolate,crospovidone and croscarmellose sodium was 
carried out and crospovidone was found most effective giving 
lowest disintegration time and wetting time. The optimum 
concentration of crospovidone was found to be around 10 percent. 
Mannitol was incorporated as a diluent to improve palatability and to 
impart sweet taste as well as to keep the tablet weight. The 
percentage of crospovidone (X under one) and mannitol (X under 
two) were studied as independent variable. Wetting time and 
disintegration time were selected as independent variable( 
response y), based on multible linear regression analysis it was 
concluded that disintegration time and wetting time could be 
obtained when X1 is kept at high level and X2 is kept at low level. 
¾ Abdul RY et al., (2005) have patented instant dissolving tablet 
composition for Loratidine and Desloratidine. The invention was 
based on the choice of a novel disintegrant,PHARMABUST a 
proprietary formulation based on mannitol.instant dissolving tablets 
of loratidine and desloratidine was prepared by direct compression 
method. 
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¾ Min-young heo et al., (2005) have studied the effect of 
microemulsifying excipient in polyethylene glycol 6000 solid 
dispersion on enhanced dissolution and bioavailability of 
Ketaconazole. When the hydrophilic or lipophilic excipients were 
combined and incorporated into PEG based SDs a remarkable 
enhancement of the dissolution rate was observed. The PEG based 
SDs incorporating a self microemulsifying drug delivery system 
(SMEDDS) or (ME) were also useful at improving dissolution rate 
by forming a microemulsion or dispersible particles with the 
aqueous medium. 
¾ Patel M.M et al.,(2006), prepared solid dispersion of Valdecoxib 
with mannitol, polyethylene glycol 4000, and PVP K-12, were 
prepared with a view to increase its water solubility. Valdecoxib 
solid dispersion with PVP K-12 showed maximum drug release 
hence, the tablet formulation containing valdecoxib PVP K-12 solid 
dispersion, was prepared with a view to improve its water 
solubility.the drug release profile was studied in 0.1 N Hcl and the 
release profile was better than conventional marketed tablet. 
¾ Singh et al., (2006) have formulated and patented fast dissolving 
composition of various drugs with prolonged sweet taste. 
Preparation of non sugar sweetener in mucoadhesive form was 
prepared by using aspartame and mucoadhesive polymer such as 
PVM/MA copolymer,carbomer etc.This non sugar mucoadhesive 
sweetener was utilized to prepare fast dissolving tablets of 
Nimesulide,Ibuprofen,Cisapride and Cetrizine 
¾ Leonardi et al., (2007) have studied dissolution properties of 
Prednisone by preparing SDs with PEG 6000 by solvent 
evaporation method. The SDs resulted in increased dissolution rate. 
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The improved dissolution rate was demonstrated by both X-ray 
diffraction and SEM, a decreased crystallinity of Prednisone. 
Tablets containing those SDs had dissolution profile that was better 
than those of CTs without PEG 6000.this indicated that PEG 6000 
is a suitable excipient for the development of Prednisone fast 
release tablets.  
¾ Naveen et al.,  (2007) have studied enhancement of dissolution and 
mathematical modeling of drug release of a poorly water-soluble 
drug (Rofecoxib) using water-soluble carriers viz. polyethylene 
glycols (PEG 4000 and 6000), polyglycolized fatty acid ester 
(Gelucire 44/14), polyvinylpyrollidone K25 (PVP), poloxamers 
(Lutrol F127 and F68), polyols (mannitol, sorbitol), organic acid 
(citric acid) and hydrotropes. All the solid dispersions showed 
dissolution improvement vis-a`-vis pure drug to varying degrees, 
with citric acid, PVP and poloxamers as the most promising 
carriers. Solid-state characterization techniques revealed that 
distinct loss of drug crystallinity in the formulation, ostensibly 
accounting for enhancement in dissolution rate. 
¾ Swamy PV et al., (2007) have designed Orodispersible tablets of 
Meloxicam with a view to enhance pateient compliance. A 
combination of super disintegrant i.e, sodium starch glycolate-
croscarmellose sodium or sodium starch glycolate-crospovidone 
were used along with directly compressible mannitol to enhance 
mouth feel. The formulation prepared by direct compression method 
using 2% w/w sodium starch glycolate and 1.5 % w/w 
croscarmellose sodium was found to be a better formulation (t50 % 
=22 min) based on in vitro release characteristics compared to 
conventional commercial tablet(t50% =68 min). 
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¾ Sheetal et al., (2007) developed a fast dissolving tablet of 
Oxcarbazepine containing Avicel PH 102 as adiluent and Ac-Di-sol 
as a superdisintegrant by wet granulation process. An 
effective,pleasant and stable formulation containing 12% Ac-Di-sol, 
25% Avicel PH 102 and 8.5% starch as a binder was found to have 
a good hardness of 4-4.5 kg/cm2 , disintegration time of 28±5 and 
drug release of not less than 90% within 30 min. the drug release 
was found to be comparable to the marketed dispersible tablet.  
¾ Madhuri et al., (2008) have prepared rapidly dissolving Ibuprofen 
SDs by low temperature melting method using PEG 6000. 
Characterized by SEM, DSC and FTIR. They were evaluated for 
solubility, in vitro release and oral bioavailability of Ibuprofen in rats. 
Quick release of Ibuprofen from SDs in rat intestine resulted in a 
significant increase in AUC and Cmax and a significant decrease in 
Tmax over pure Ibuprofen were noted. 
¾ Jigar et al., (2008) have prepared solid dispersions of Valdecoxib 
by melt granulation technique using PVP k 30 and PEG 4000 alone 
(1:1) and in combination (1:0.5:0.5).Phase solubility studies showed 
a linear increase in Valdecoxib solubility with increase in polymer 
concentration in both the cases. FTIR studies showed the stability 
of Valdecoxib and absence of well defined Valdecoxib-PVP k 30 – 
PEG 4000 interaction. Characterization by XRD and DSC indicated 
a complete transformation of drug from crystalline to amorphous 
form. In vitro dissolution studies in 0.1 N Hcl showed a significant 
enhance in the dissolution rate when PEG 4000 and PVP k 30 were 
used in combination.  
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¾ Swamy PV et al., (2008), attempted to prepare Orodispersible 
tablets of Carbamazepine with a view to enhance patient 
compliance by direct compression method using 3² full factorial 
design. Crospovidone (2-10% w/w) was used as superdisintegrant 
and microcrystallinecellulose (0-30% w/w) was used as diluent, 
along with directly compressible mannitol to enhance mouth feel. 
The tablets were evaluated for hardness, friability, thickness, drug 
content uniformity, in vitro dispersion time, wetting time and water 
absorption ratio. Based on in vitro dispersion time (approximately 
10 s); the formulation containing 2% w/w crospovidone and 
30%w/w microcrystalline cellulose was found to be promising and 
tested for in vitro drug release pattern (in pH 6.8 phosphate buffer), 
short-term stability (at 40º/75 % RH for 3 w) and drug-excipient 
interaction. This formulation showed four-fold faster drug release 
(t25%) compared to the conventional commercial tablet formulation. 
Short-term stability studies on the formulation indicated that there 
are no significant changes in drug content and in vitro dispersion 
time (p < 0.05). 
¾ Venkatesh DP et al., (2008) have attempted to mask the taste of 
Ambroxol hydrochloride a bitter drug and to formulate into a 
Orodispersible tablet by complexation with ion exchange resins, 
which also acts as super disintegrating agents. Cation exchange 
resins like Indion-204 and Indion-234 were utilized for the sorption 
of drug. Drug-resinates was prepared in drug to resin ratio of 1:5 
and 1:6. Tablets with both the resins have shown quick 
disintegrating features, i.e., within 20 s, which is very characteristic 
of Orodispersible tablets. Also, the dispersion not showing any bitter 
taste, indicate the capability of ion exchange resins used, both as 
taste masking and super disintegrating agents. Almost more than 
90 percent of drug was released from both the formulations within  
1 hour. 
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¾ Mallikarjuna C et al., (2008) developed fast dispersible 
Aceclofenac tablets and studied the functionality of 
superdisintegrants such as croscarmellose sodium, sodium starch 
glycolate and crospovidone. on wetting time, disintegration and in 
vitro dissolution profile. Disintegration time and dissolution 
parameters(t50% and t90% ) decreased with increase in the level of 
croscarmellose sodium.  
¾ Patel DM et al., (2008) attempted to optimize the fast dissolving 
Etoricoxib tablets prepared by sublimation technique. Granules 
containing Etoricoxib, menthol, crospovidone, aspartame and 
mannitol were prepared by wet granulation. Menthol was sublimed 
from the granules by exposing the granules to vaccum. The porous 
granules were then compressed in to tablets. Alternatively, tablets 
were prepared first and later exposed to vacuum. A 3 2 full factorial 
design was applied to investigate the combined effect of 
2 formulation variables: amount of menthol and crospovidone. 
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MATERIALS AND EQUIPMENTS 
Table 3: Materials used 
Name of the materials Name of company 
Domperidone Carewell pharma, Chennai 
PEG 4000 Sisco research lab pvt ltd 
PEG 6000 Himedia lab pvt ltd 
PEG 8000 Himedia lab pvt ltd 
Dimetthylformamide Qualigens fine chemicals 
Methanol SD fine chem. Ltd 
Ammonium acetate SD fine chem. Ltd 
Dioxane SD fine chem. Ltd 
Glacial acetic acid Qualigens fine chemicals 
Hydrochloric acid SD fine chem. Ltd 
 
Table 4: Equipments used 
Name of equipment Name of company 
Vacuum pump Gelman sciences 
Dissolution apparatus Labindia Disso 2000                            
UV spectrometer Jasco V 530 
Alphadigidoc TM Alpha Innotech corporation 
FT IR  spectrometer (Jasco-FT-IR 8201 PC) 
pH tester 1 (water proof) Oakton instruments. 
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ANALYTICAL METHOD 
 Domperidone a prokinetic drug used in the treatment of nausea and 
vomiting chemically known as 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-
yl) propyl] piperidin-4-yl] -1H-benzimidazol-2-one.The estimation of 
Domperidone in the formulations can be done by various HPLC,HPTLC 
and spectrophotometric methods. 
 
Methods for the estimation of Domperidone in tablet formulation 
 HPLC method 
 This method allows the determination of 100- 500 ng/spot of 
Domperidone using mobile phase composition as n-butanol: glacial acetic 
acid: water (9.3: 0.25: 0.5, v/v/v). When densitometric analysis carried out 
in the absorbance mode at 288 nm, the Rf value will be 0.21, limit of 
detection 30 ng/spot and limit of quantification 65 ng/spotSusheel.J.V,et al., 2007.   
 
 HPTLC method 
 This method allows determining Domperidone on aluminium sheets 
of silica gel 60 F254  using ethyl acetate: methanol: benzene (40:20:40 v/v) 
as mobile phase at a linear concentration range of 120-360 ng/spot. The 
limit of detection 40.53 ng/spot. Mean analytical recovery in Domperidone 
capsules 99.48± 1.15 Bhavesh P.,et al,2007. 
 
 UV spectrophotometric method  
 Domperidone can be estimated from solid dosage forms by          
UV spectrophometric method at λ max 284 nm. Beer’s law linearity range is  
8 -30 mcg/ml Prabu SL.,et al, 2008. 
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ANALYTICAL METHODOLOGY USED IN THE PRESENT STUDY 
Procedure for standard graph preparation of Domperidone  BP 1996 
 
 Accurately weighed 100 mg of Domperidone was dissolved in  
100 ml of methanol taken in a properly cleaned and dried volumetric flask. 
From this solution 10 ml is made up to 100 ml with methanol which will 
give the stock solution 100 mcg/ml. 
 From this solution pipette out 0.5,1.0,1.5,2.0,2.5 and 3.0 ml, which 
were transferred into a series of 10 ml volumetric flasks and the final 
volume was brought up to 10 ml with 0.1 M HCl to get a concentration of  
5-30 mcg/ml. A blank was also prepared. The absorbance was measured 
at 286 nm and the standard graph was plotted against concentration 
(mcg/ml) Vs absorbance. The results were given in Table 5 and Figure 2.  
 
Table  5 : Standard graph of Domperidone 
Concentration (mcg/ml) Absorbance at 286 nm 
0 0.000 
5 0.140 
10 0.284 
15 0.426 
20 0.563 
25 0.712 
30 0.855 
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Figure 2: Standard graph of Domperidone at 0.1 M HCl 
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EXPERIMENTAL METHODOLOGY 
 Domperidone a prokinetic dopamine receptor antagonist indicated 
for the treatment of nausea and vomiting. As Domperidone is practically in 
soluble in water the absorption is dissolution rate limited. Solid dispersion 
technology can be used to improve the in vitro and in vivo dissolution 
properties of poorly soluble drugs.PEG 4000,PEG 6000 and PEG 8000 
were used as carriers in the preparation of Domperidone solid dispersion 
in the ratios of 1:1, 1:3 and 1:9 by solvent evaporation method using 
Dimethylformamide (DMF)  as solvent.  
 
Procedure for preparation of Domperidone solid dispersion by 
Solvent evaporation method  
  Respective amount of carrier was dissolved in required amount of 
DMF taken in a conical flask to get a clear completely soluble polymer 
DMF solution, magnetic stirrer was used for this purpose. The weighed 
amount of Domperidone was added to this solution carefully with constant 
stirring. Stirring was continued until the drug was completely incorporated 
in solvent. Then the solvent was removed by evaporation at 40° C under 
vacuum. The mass obtained was dried, crushed, pulverized and sifted 
through mesh no. 80.The details were given in Table 6. 
 
Physical mixture (PM) 
 Drug: Carrier ratio of 1:1 was used to prepare physical mixture 
(1000 mg of drug and 1000 mg of carrier). The drug and carrier were 
mixed thoroughly in a mortar. This was done by geometric dilution 
technique to ensure homogenous distribution. 
 
 
 
Chapter 8 Experimental Methodology  
 53
Table 6: Drug carrier ratio and respective amount taken 
Solid 
dispersion 
Drug  carrier 
ratio Drug (mg) Carrier (mg) 
1:1 1000 1000 
1:3 500 1500 Domperidone- PEG 4000 
1:9 200 1800 
1:1 1000 100 
1:3 500 1500 Domperidone- PEG 6000 
1:9 200 1800 
1:1 1000 100 
1:3 500 1500 Domperidone- PEG 8000 
1:9 200 1800 
 
 
CHARACTERIZATION AND EVALUATION OF DOMPERIDONE SOLID 
DISPERSION 
a. Thin layer Chromatography  
b. IR spectral Analysis  
c. Powdered  X-ray Diffraction studies 
d. Differential Scanning Calorimetry  
e. Scanning electron microscopy 
f. Drug content uniformity 
g.  In vitro dissolution studies  
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Thin layer chromatography (TLC) 
 A thin layer chromatographic method was also carried to study the 
interaction between the drug and carriers and also to confirm the chemical 
satiability of the solid dispersions prepared. For this, the pure drug and the 
solid dispersions prepared with various carriers by solvent evaporation 
method were subjected to chromatographic studies British Pharmacopoeia 1996.  
 
 The TLC system used for this study is given below. 
 
Precoated TLC Plates :  Manufactured by SD Fine chemicals 
Ltd, Mumbai 
Adsorbent Layer :  Silica gel GF 254. 
Layer Thickness :  250 &µm. 
Separation technique : Ascending 
Chamber Saturation :  The chamber was lined on three 
sides with filter paper and saturated 
for 30 minutes.        
Mobile phase :  Methanol: Dioxan: Ammonium  
  acetate solution [40:40:20 % v/v]90. 
Preparation of sample :  A suitable amount of pure drug or 
equivalent solid dispersion dissolved 
in Methanol and used for spotting. 
Amount applied :  5 µl.  
Detection :  Dry the plate in a current of warm air 
for 15 min and expose it to iodine 
vapor until the spot appear. 
Examine in day light. 
 The Rf values obtained were given in the Table 7 and thin layer 
chromatograms of various solid dispersions were shown in Figure 3.  
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Table 7: TLC data for various solid dispersions systems 
Solid dispersion 
Drug carrier 
ratio 
Rf value No of spots 
Pure 
Domperidone 
--- 0.70 single 
1:1 0.71 single 
1:3 0.71 single 
Domperidone-
PEG 4000 
1:9 0.71 single 
1:1 0.70 single 
1:3 0.70 single 
Domperidone- 
PEG 6000 
1:9 0.71 single 
1:1 0.70 single 
1:3 0.71 single 
Domperidone- 
PEG 6000 
1:9 0.71 single 
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     Pure Domperidone          DOM- PEG 4000 SD 
      
        
                
    DOM- PEG 6000 SD           DOM- PEG 8000 SD 
 
Figure 3: Thin layer chromatogram of various solid dispersions  
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IR SPECTRAL ANALYSIS 
 Fourier Transform (FTIR) spectra of the samples were obtained in 
the range of 400-4000 cm-1 using a Jasco-FT-IR 8201 PC 
Spectrophotometer (Jasco.Essex) by the KBr disc method. The IR Spectra 
obtained are given in Figure 4 - 8. 
 
Figure 4: IR spectrum of pure Domperidone 
 
Figure 5: IR spectrum of pure PEG 4000 
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Figure 6: IR spectrum of solid dispersions of Domperidone with  
PEG 4000 (1:1) 
 
Figure 7: IR spectrum of solid dispersions of Domperidone with  
PEG 4000 (1:3) 
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Figure 8: IR spectrum of solid dispersions of Domperidone with  
PEG 4000 (1:9) 
 
Powder X-ray diffractometry 
 X-Ray Powder Diffractometry is one of the most powerful and 
established technique for material structural analysis, capable of providing 
information about the structure of a material at the atomic level. Low and 
High temperature measurement facilities are available Chidavaenzi O.C and 
Buckton G,2001. 
 The Temperature attachment enables analysis from -170oC to 
+450oC under vacuum.  Change in unit cell dimensions, structural changes 
at phase transitions etc, as a function of temperature   can be determined. 
The Powder X-ray Diffraction Patterns were recorded using Bruker AXS 
D8 advance instrument for pure Domperidone, and solid dispersions of 
DOM-PEG 4000 (1:1,1:3 and 1:9) were carried out and the results were 
given in Figure 9 - 12 .  
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The specifications of the instrument were given below  
Make/Model : Bruker AXS D8 Advance 
Configuration : Vertical, Theta/2 Theta geometry 
Measuring circle diameter : 435, 500, and 600 mm predefined 
Angle range : 360° 
Max. Usable angular range: : 3° to 135° 
Smallest addressable increment : 0.001° 
Max. angular speed : 30°/s 
X-ray source : Cu, Wavelength 1.5406 A°  
Detector  
Temperature attachment  
Make /Model 
Temperature Range  
:
:
:
Si(Li) PSD 
Anton Paar, TTK 450
-170 °C to +450 °C 
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Figure 9: X- ray diffraction studies of pure Domperidone 
 
 
 
 
Figure 10: X- ray diffraction studies of solid dispersions of 
Domperidone with PEG 4000(1:1) 
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Figure 11: X- ray diffraction studies of solid dispersions of 
Domperidone with PEG 4000 (1:3) 
 
 
 
Figure 12: X- ray diffraction studies of solid dispersions of 
Domperidone with PEG 4000(1:9) 
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Differential Scanning Calorimetry 
 DSC (Differential Scanning Calorimetry) measures the amount of 
heat energy absorbed or released by a sample, as it is heated, cooled or 
held at a constant temperature. The DSC thermograms were taken for 
pure Domperidone and solid dispersions of DOM-PEG 4000(1:1, 1:3 and 
1:9) and were given in Figure 13 – 17.The specifications of the instrument 
were given below 
 
Make/Model  : Mettler Toledo DSC 822e  
Temperature Range  : -150 °C to max. 700°C 
Measurement range : ± 350 mW at RT 
Measurement resolution : 0.04 mW at RT 
Temperature Accuracy : ± 0.2°C 
Temperature reproducibility : ± 0.1°C 
Heating rate : RT to 700°C in 7 min 
Cooling rate : + 100°C to – 100°C in 15 min 
Sampling rate : Max 10 values / sec 
 
 The applications of DSC are numerous, either for routine quality 
control measurements or in research, where high sensitivity and flexibility 
are important aspects.Applications include study of melting behavior, glass 
transition, specific heat anomaly, oxidation stability, chemical kinetics etc 
Corrigan.D.O, Healy.A.M,2002
. 
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Figure 13: DSC Thermogram of pure Domperidone 
 
 
 
Figure 14: DSC Thermogram of solid dispersion of Domperidone with 
PEG 4000 (1:1) 
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Figure 15: DSC Thermogram of solid dispersion of Domperidone with 
PEG 4000 (1:3) 
 
 
Figure 16: DSC Thermogram of solid dispersion of Domperidone with 
PEG 4000 (1:9) 
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Figure 17: DSC Thermograms of pure drug and solid dispersions 
 
Scanning Electron Microscopy 
 Scanning electron microscopy (SEM) is a method for high 
resolution surface imaging.  The SEM uses an electron beam for surface 
imaging. The advantages of SEM over light microscopy are greater 
magnification and much larger depth of field. The morphological 
characteristics of pure Domperidone and solid dispersion DOM-PEG 
4000(1:1) were studied using the SEMFoster.T.P and Leatherman.M.W,1995. The 
SEM results were shown in Figure 18 and 19.    
 
Specifications of SEM-EDS used for the analysis follows.   
SEM Make : JEOL Model JSM – 6390LV 
EDS Make : JEOL Model JED – 2300 
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Resolution : 3 nm (Acc V 30 KV, WD 8 mm, SEI) 
  : 8 nm(Acc V 3.0 KV, WD 6 mm, SEI) 
  : 15 nm(Acc V 1.0 KV, WD 6 mm, SEI) 
Magnification : 5 × to 300, 000 × (Both in High and 
Low Vacuum Modes) 
Image Modes  SEI, BEI 
Probe Current           : 1 pA to 1mA 
High vacuum resolution  3 nm 
Low vacuum resolution  4 nm 
Specimen Stage    
Type  Eucentric 
Manual type  5 Axes (X, Y, Z, R, T), Manual 
Control 
Tilt  +90º 
Specimen holder  10 mm diameter. 
Maximum loadable specimen size : 1 
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Figure 18: SEM of pure Domperidone (10000 X) 
 
 
 
Figure 19: SEM of Domperidone PEG 4000 SD (1:1) (10000 X) 
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DRUG CONTENT UNIFORMITY  
 The prepared Domperidone solid dispersion was tested for drug 
content uniformity. From each batch of solid dispersion prepared in 
different ratios, solid dispersion equivalent to 10mg of Domperidone were 
taken and analyzed for drug content uniformity.  
 
Estimation of Domperidone in solid dispersion by UV Spectroscopy    
 Accurately weighed amount of Domperidone solid dispersion was 
dissolved in 100 ml of 0.1M HCl in 100ml volumetric flask which was 
previously clean and dry. This solution after suitable dilution was 
measured for absorbance at 286 nm in a Jasco V530 UV visible 
spectrophotometer. The results were shown in Table 8.  
 
Table 8: Drug content uniformity in Domperidone SDs 
Solid dispersion 
 
Drug : 
carrier 
Amount 
of SD 
taken(mg)
Expected 
amount of 
Domperidone 
in SD (mg) 
Domperidone 
estimated by 
spectrophoto
meter (%) 
1:1 20 10 98.57±1.45 
1:3 40 10 100.19±0.76 Domperidone PEG 4000 
1:9 100 10 101.84±0.48 
1:1 20 10 99.48±0.93 
1:3 40 10 101.96±0.82 Domperidone PEG 6000 
1:9 100 10 99.78±0.59 
1:1 20 10 102.67±0.71 
1:3 40 10 102.53±0.44 Domperidone PEG 8000 
1:9 100 10 101.6±0.35 
n = 3  ±, Sd 
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In vitro dissolution studies 
 The dissolution studies are the most important part of the evaluation 
of solid dispersion, where the dissolution of pure drug and solid dispersion 
is carried out. Dissolution rate studies of various solid dispersions were 
carried out in 0.1 M HCl using USP XXII dissolution apparatus (labIndia 
Disso 2000). 
 
Dissolution method 
 900 ml of 0.1 M HCl was used as dissolution medium. SDs 
equivalent to 10 mg of Domperidone was taken in a hard gelatin capsule; 
a stainless steel wire was wound around the capsule to sink. The paddle 
type stirrer was adjusted to 50 rpm. The temperature was maintained at 
37°±2°c. 5 ml aliquot dissolution media was withdrawn at different time 
intervals and volume withdrawn was replaced with fresh quantity of 
dissolution medium. The samples were analyzed for Domperidone after 
suitable dilution by measuring the absorption values at 286 nm using 
Jasco V 530 UV visible spectrophotometer, 0.1 M HCl was used as a 
blank. The percentage of Domperidone dissolved at various time intervals 
was calculated and plotted against time. T50, T90 values were calculated 
from these dissolution curves. The results are shown in Table 9-12 and  
Figure 21-24.   
 
Figure 20: Dissolution apparatus (Labindia Disso 2008) 
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Table 9: Dissolution profile of Domperidone from PEG 4000 solid 
dispersion at different drug carrier ratios 
Percentage release of Domperidone from different drug 
carrier ratios Time in 
minutes Pure drug 
10 mg 
Physical 
mixture 1:1 1:3 1:9 
0 0 0 0 0 0 
5 2.78±0.39 16.33±1.40 27.00±0.52 21.83±1.42 23.85±0.76
15 8.41±0.74 49.08±0.86 81.05±0.66 65.56±0.90 74.64±0.12
30 15.10±0.46 73.80±0.91 88.62±0.14 89.04±0.39 97.39±0.09
45 24.96±0.62 74.33±1.34 89.29±0.63 90.37±0.56 98.76±0.86
60 31.09±1.2 78.37±1.21 95.77±0.72 92.15±0.78 99.12±1.56
n = 3,± Sd 
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Figure 21: Dissolution profile of Domperidone from PGE 4000 solid 
dispersion at different drug carrier ratios 
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Table 10: Dissolution profile of Domperidone from PGE 6000 solid 
dispersion at different drug carrier ratios 
Percentage release of Domperidone  from different drug 
carrier ratios Time in 
minutes Pure drug 
10 mg 
Physical 
mixture 1:1 1:3 1:9 
0 0 0 0 0 0 
5 2.78±0.39 15.42±1.20 18.87±1.56 16.68±0,91 25.73±0.14
15 8.41±0.74 48.51±0.52 44.28±0.39 50.13±1.34 77.28±0.63
30 15.10±0.46 50.87±0.63 56.44±0.74 90.38±1.21 97.79±0.72
45 24.96±0.62 53.02±0.86 62.49±0.46 97.28±0.52 98.58±0.12
60 31.09±1.2 55.87±0.12 72.09±0.72 98.13±0.66 99.31±0.76
n = 3,± Sd 
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Figure 22: Dissolution profile of Domperidone from PEG 6000 solid 
dispersion at different drug carrier ratios 
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Table 11: Dissolution profile of Domperidone from PEG 8000 solid 
dispersion at different drug carrier ratios 
Percentage release of Domperidone from different drug 
carrier ratios Time in 
minutes Pure drug 
10 mg 
Physical 
mixture 1:1 1:3 1:9 
0 0 0 0 0 0 
5 2.78±0.39 13.68±1.56 16.82±0.98 18.27±0.68 28.48±1.60
15 8.41±0.74 47.67±1.33 51.29±0.65 54.82±1.56 85.48±1.72
30 15.10±0.46 52.95±2.10 59.87±0.83 76.68±0.73 96.36±0.56
45 24.96±0.62 58.83±1.12 64.38±1.20 78.48±0.82 97.74±0.62
60 31.09±1.2 62.49±1.84 74.56±0.95 80.06±1.34 99.36±1.50
n = 3,± Sd 
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Figure 23:  Dissolution profile of Domperidone from PEG 8000 solid 
dispersion at different drug carrier ratios 
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Table 12: Percentage release of Domperidone from various solid 
dispersions 
Percentage release of Domperidone from 
DOM: PEG 4000 DOM: PEG 6000 DOM: PEG 8000 Time in 
minutes Pure 
drug 1:1 1:3 1:9 1:1 1:3 1:9 1:1 1:3 1:9 
0 0 0 0 0 0 0 0 0 0 0 
5 2.6 27.00 21.83 23.85 18.87 16.68 25.73 16.82 18.27 28.48 
15 4.5 81.05 65.56 74.64 44.28 50.13 77.28 51.29 54.82 85.48 
30 10.2 88.62 89.04 97.39 56.44 90.38 97.79 59.87 76.68 96.36 
45 15.75 89.29 90.37 98.76 62.49 97.28 98.58 64.38 78.48 97.74 
60 31.09 95.77 92.15 99.12 72.09 98.13 99.31 74.56 80.06 99.36 
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Figure 24: Dissolution profile of Domperidone from various  
solid dispersions 
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Table 13:  Relation between % carrier and T50, T90 values for 
Domperidone –PEG 4000 solid dispersions 
% of drug % of carrier T50 (min) T90 (min) 
1 0 94.9 - 
1 1 9.5 47.5 
1 3 12.0 45.0 
1 9 10.5 25.5 
 
Table 14: Relation between % carrier and T50, T90 values for 
Domperidone- PEG 6000 solid dispersions 
% of drug % of carrier T50 (min) T90 (min) 
1 0 94.9 - 
1 1 22.5 - 
1 3 15.0 30 
1 9 10.0 24.5 
  
Table 15:  Relation between % carrier and T50, T90 values for 
Domperidone- PEG 8000 solid dispersions 
% of drug % of carrier T50 (min) T90 (min) 
1 0 94.9 - 
1 1 14.5 - 
1 3 14.0 - 
1 9 8.5 22.5 
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Table 16: Percentage Domperidone undissolved from pure form and 
from PEG 4000 solid dispersions at various drug carrier ratios 
 
percentage Domperidone undissolved from Time in 
minutes Pure drug  10 mg PM 1:1 1:1 1:3 1:9 
0 100 100 100 100 100 
5 97.22 83.67 73.00 78.17 95.15 
15 91.59 50.92 18.95 34.44 85.36 
30 84.90 26.20 11.38 10.96 2.61 
45 75.04 25.67 10.71 9.63 1.24 
60 68.91 21.63 4.23 7.85 0.88 
Table 17: LOG Percentage Domperidone undissolved from pure form 
and from PEG 4000 solid dispersions at various drug carrier ratios 
 
Percentage domperidone undissolved from (log 
percentage undissolved) Time in 
minutes Pure drug  
10 mg PM 1:1 1:1 1:3 1:9 
0 2 2 2 2 2 
5 1.9877 1.9225 1.8633 1.8930 1.9784 
15 1.9618 1.7068 1.2776 1.5370 1.9312 
30 1.9289 1.4183 1.0561 1.0398 0.4166 
45 1.8752 1.4094 1.0297 0.9836 0.0934 
60 1.8382 1.3350 0.6263 0.8948 0.055 
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Figure 25: Percentage Domperidone undissolved from pure form and 
from PEG 4000 solid dispersions at various drug carrier ratios 
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Table 18: Percentage Domperidone undissolved from pure form and 
from PEG 6000 solid dispersions at various drug carrier ratios 
 
Percentage domperidone  undissolved from Time in 
minutes Pure drug  10 mg PM 1:1 1:1 1:3 1:9 
0 100 100 100 100 100 
5 97.22 84.58 81.13 83.32 74.27 
15 91.59 51.49 55.72 49.87 22.72 
30 84.90 49.13 43.56 9.62 2.21 
45 75.04 46.98 37.51 2.72 1.42 
60 68.91 44.13 27.91 1.87 0.69 
Table 19: LOG Percentage Domperidone undissolved from pure form 
and from PEG 6000 solid dispersions at various drug carrier ratios 
 
Percentage domperidone  undissolved from (log 
percentage undissolved) Time in 
minutes Pure drug  
10 mg PM 1:1 1:1 1:3 1:9 
0 2 2 2 2 2 
5 1.9877 1.9272 1.9091 1.9207 1.8708 
15 1.9618 1.7117 1.7460 1.6978 1.3564 
30 1.9289 1.6913 1.6390 0.9831 0.3443 
45 1.8752 1.6719 1.5741 0.4345 0.1522 
60 1.8382 1.6447 1.4457 0.2718 0.1611 
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Figure 26: Percentage Domperidone undissolved from pure form and 
from PEG 6000 solid dispersions at various drug carrier ratios 
Chapter 8 Experimental Methodology  
 78
Table 20: Percentage Domperidone undissolved from pure form and 
from PEG 8000 solid dispersions at various drug carrier ratios 
 
Percentage  Domperidone undissolved from Time in 
minutes Pure drug  10 mg PM 1:1 1:1 1:3 1:9 
0 100 100 100 100 100 
5 97.22 86.32 83.18 81.73 71.52 
15 91.59 52.33 48.71 45.18 14.52 
30 84.90 47.05 40.13 23.32 3.64 
45 75.04 41.17 35.62 21.52 2.26 
60 68.91 37.51 25.44 19.94 0.64 
Table 21:  LOG Percentage Domperidone undissolved from pure form 
and from PEG 8000 solid dispersions at various drug carrier ratios 
 
Percentage  Domperidone undissolved from (log 
percentage undissolved) Time in 
minutes Pure drug  
10 mg PM 1:1 1:1 1:3 1:9 
0 2 2 2 2 2 
5 1.9877 1.9361 1.9200 1.9123 1.8544 
15 1.9618 1.7187 1.6876 1.6549 1.1619 
30 1.9289 1.6725 1.6034 1.3677 0.5611 
45 1.8752 1.6145 1.5516 1.3328 0.3541 
60 1.8382 1.5741 1.4055 1.2997 0.1938 
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Figure 27:  Percentage Domperidone undissolved from pure form and 
from PEG 8000 solid dispersions at various drug carrier ratios 
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Table 22: First order rate constant for Domperidone dissolution from 
various solid dispersions 
Sample K (min-1) 
Pure drug 0.0046 
DOM:PEG 4000  
PM 0.025 
1:1 0.048 
1:3 0.043 
1:9 0.089 
DOM: PEG 6000  
PM 0.011 
1:1 0.018 
1:3 0.071 
1:9 0.078 
DOM:PEG 8000  
PM 0.013 
1:1 0.020 
1:3 0.027 
1:9 0.071 
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RESULTS AND DISCUSSION 
 Solid dispersion of Domperidone was prepared by depositing on the 
polymers namely PEG 4000, PEG 6000 and PEG 8000 by solvent 
evaporation method. Solid dispersions at drug: carrier ratios (1:1, 1:3, 1:9) 
were prepared and summarized in Table 6 .All solid dispersions prepared 
were found to be fine and free flowing powders. The percent of drug 
content in the solid dispersions were given in table .8. There was no 
significant loss of drug during the preparation of solid dispersions and the 
proportion of drug and carrier remained the same as that initially taken. 
The estimated drug content of the prepared solid dispersions was in the 
range of 100.95±1.4%.  
 
 The prepare solid dispersions were characterized by TLC, FTIR, X-
ray diffraction and Differential Scanning Calorimetry    
 
THIN LAYER CHROMATOGRAPHY 
 In TLC studies as per the data given in Table 7, Domperidone 
dispersed in various carriers showed the similar Rf (0.70) value as pure 
compound and no additional spots were detected. TLC studies thus 
indicated no interaction between Domperidone and carriers used in the 
solid dispersions. This observation also indicated that Domperidone was 
not decomposed during the preparation of solid dispersions. 
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FT-IR SPECTRAL ANALYSIS 
 Compatibility studies of Domperidone and the carriers PEG 
4000(1:1, 1:3 and 1:9) were carried out by using FT-IR. The IR spectra 
obtained are given in Figure 4 - 8. The IR spectrum of Domperidone 
showed characteristic intense absorbance band at 3406.64 cm-1 (Aromatic 
C--H stretching), 1691.27 cm-1 (C=O stretching due to 5 member imides), 
1485.88 cm-1, 1590.99 cm-1 (C=C stretching), 760.78 cm-1 (mono 
substituted Benzene) and 1348 cm-1 (–NH stretching). 
PEG 4000 shown characteristic vibrations at 2881.13 cm-1 (C—H 
stretching in CH2), 1110.8 cm-1 (C—O stretching due to ether), 3699.76 cm-
1 (O--H stretching due to free OH group). 
IR spectra of Domperidone solid dispersions at 1:1, 1:3 and 1:9 
showed insignificant shifts in peaks for both Domperidone and PEG 4000, 
suggesting the absence of interaction between Domperidone and        
PEG 4000.  
 
POWDER X- RAY DIFFRACTION  
 The presence of numerous distinct peaks in the X-ray diffraction 
spectrum indicate that Domperidone was present as a crystalline material 
with distinct intense diffraction peaks appearing at a diffraction angle of 2θ 
at 4.93o,9.56o,14.29o,15.85o, also less intense peaks at 25.10o,29.31o and 
31.75o. PEG 4000 exhibited a distinct pattern with diffraction peaks at 
angle 2θ at 19.41o and 23.47o, Figure 9-12.  
 Solid dispersion systems showed fewer, broader, and less intense 
peaks when compared to that of pure drug. When PEG 4000 content was 
increased from 50 % (1:1 SD) to 90 % (1:9 SD), some characteristic peaks 
of Domperidone (25.10o, 29.31o) were disappeared. The position of PEG 
4000 patterns in SD systems were the same as super imposable which 
ruled out the possibility of chemical interaction between Domperidone and 
PEG 4000. These results suggest that Domperidone was dispersed 
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homogenously in an amorphous state or dissolved into PEG 4000 Lin CW and 
Cham TM, 1996
. 
 
DIFFERENTIAL SCANNING CALORIMETRY    
 The DSC details were given in Figure 13 - 17. The DSC curve of 
pure Domperidone exhibited a single endothermic response corresponding 
to the melting point of the drug. Onset of melting was observed at 249.5o 
C. All Domperidone PEG 4000(1:1, 1:3 and 1:9) solid dispersions showed, 
a constant melting at approximately 55.8o C corresponding to the melting 
point of PEG 4000 .The presence of DOM in the SDs hardly affected the 
melting point of PEG 4000, but a small amount of PEG 4000 caused 
depression of melting point of Domperidone. 
 Solid dispersions exhibited two endothermic transitions 
corresponding to the melting of the polymer and of the drug. These 
similarities suggest the absence of chemical interaction between both 
species. The melting point of Domperidone in the SDs decreased as the 
concentration of polymer increases from 234.3o C (50 %) to 176.8o C 
(90%) and shifted to the lower melting point. This shows that the transition 
of Domperidone from lower energy crystalline state to higher energy 
amorphous state.  
 
SCANNING ELECTRON MICROSCOPY 
 The scanning electron microscopy was carried out and photos were 
taken for the pure DOM and DOM-PEG 4000(1:1) solid dispersion, photos 
were given in Figure 18 &19. The SEM photos revealed that there was a 
morphological change of pure Domperidone from crystalline nature to 
amorphous nature in the solid dispersion. 
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DISSOLUTION STUDIES  
 The dissolution profiles of pure drug, physical mixture and various 
solid dispersions were given in Table 9-12 and Figure 21-24. The time 
required to dissolve 50% of the drug T50 was taken as a basis for 
comparison of the dissolution rate. It was evident that the rate of 
dissolution of pure Domperidone was very slow, only 50 % of the drug was 
dissolved after 1.5 hr. T50 values decreased from 1.5 hr for the pure drug 
to less than 15 min for DOM-PEG 4000 solid dispersions. First order rate 
constant “K” values found to be increased when the carrier concentration 
was raised indicating the fast dissolution of Domperidone at higher carrier 
concentration The increased dissolution rate from SDs can be attributed to 
the lack of crystallinity and  increased wettability . 
 Dissolution rate of Domperidone from its physical mixture 
containing 50 % w/w of Domperidone was significantly higher than for the 
pure drug. T50 value was reached after 35 min for the PM. Dry mixing 
brings the drug in close contact with the hydrophilic polymer and the 
increased dissolution rate can thus be explained as a result of increased 
wettability and dispersibility of Domperidone. Indeed, during dissolution 
experiments, it was noticed that physical mixtures immediately sink to the 
bottom of the dissolution vessel as solid dispersions do, whereas the pure 
drug floats for a longer period on the surface of the dissolution medium. 
  Among the solid dispersions prepared DOM-PEG 4000(1:9), DOM-
PEG 6000(1:9) and DOM-PEG 8000(1:9) gave the highest dissolution 
rate. SDs of DOM- PEG 4000(1:1, 1:3 and 1:9) gave dissolution rate more 
than 90% at 45 min when compared to other SDs. The rate of dissolution 
of SDs showed 3 fold increase when compared to pure drug.   
 The order of dissolution of Domperidone from various carriers was  
DOM-PEG 8000(1:9) > DOM-PEG 6000(1:9) > DOM-PEG 4000(1:9) > 
DOM-PEG 6000(1:3) > DOM-PEG 4000(1:1) > DOM-PEG 4000(1:3) > 
DOM-PEG 8000(1:3), DOM-PEG 8000(1:1)> DOM-PEG 6000(1:1) >  pure 
drug. 
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FORMULATION AND EVALUATION OF 
ORODISPERSIBLE TABLETS OF SELECTED 
DOMPERIDONE SOLID DISPERSION 
 
Domperidone a prokinetic dopamine receptor antagonist indicated 
for the treatment of nausea and vomiting as well as in chemotherapy 
induced nausea and vomiting. As the oral bioavailability of Domperidone is 
only 13% to 17 % due poor aqueous solubility and hepatic first pass 
metabolism, attempts were made to improve bioavailability by formulating 
Orodispersible tablets of selected solid dispersions using non sugar muco 
adhesive sweetener (NSMAS) for imparting good mouth feel and thus 
compliance. ODTs can improve bioavailability of drugs undergoing hepatic 
metabolism by facilitating drug for presystemic absorption and also by 
bypassing hepatic first pass effect.   
PREPARATION OF NON SUGAR MUCOADHESIVE SWEETENER 
(NSMAS) 
 Carbomer was dispersed in 20 ml of water. Then aspartame was 
granulated with Carbomer solution and dried at 40o C. Sift through 60 
mesh sieve singh et al., 2006. 
 
Table 23: Formula of Non Sugar Mucoadhesive Sweetener (NSMAS) 
S.No Ingredients Amount 
1 Aspartame 20 gm 
2 Carbomer 0.4 gm 
3 Water 20 ml 
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Formulation of Orodispersible tablets 
 Domperidone solid dispersion in PEG 4000 at a drug carrier ratio of 
1:1, 1:3 and 1:9 were formulated into tablets using directly compressible 
mannitol as diluent and crosscarmellose sodium as superdisintegrant in 
2%, 4% as well as 8% with other additives and evaluated for drug release 
characteristics. Tablets containing solid dispersion equivalent to 10 mg of 
Domperidone were prepared using various additives given in Table 24. 
 
Table 24: Formula of Domperidone Orodispersible tablets  
Formulations (mgs) S. 
No Ingredients F1 F2 F3 F3 F4 F5 F7 F8 F9 
1 
Domperidone: 
PEG 4000(1:1) 
drug carrier 
ratio. 
20 20 20       
2 
Domperidone: 
PEG 4000(1:3) 
drug carrier 
ratio. 
   40 40 40    
3 
Domperidone: 
PEG 4000(1:9) 
drug carrier 
ratio. 
      100 100 100
5 
Directly 
compressible 
mannitol 
168 164 156 148 144 136 88 84 76 
6 Croscarmellose sodium 4 8 16 4 8 16 4 8 16 
7 Magnesium stearate 2 2 2 2 2 2 2 2 2 
8 Talc 2 2 2 2 2 2 2 2 2 
9 
Non sugar 
mucoadhesive 
sweetener(NSM
AS) 
4 4 4 4 4 4 4 4 4 
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Table 25: Materials used for tablet formulation 
Name of the materials Name of company 
Domperidone: PEG 4000 (1:1, 1:3, 1:9) 
drug carrier ratio Prepared in previous chapter 
Domperidone Carewell pharma, Chennai 
Directly compressible mannitol IPCA Ltd, Mumbai. 
Croscarmellose sodium Maple biotech pvt Ltd 
Talc Himedia Laboratories Pvt Ltd 
Aspartame Himedia Laboratories Pvt Ltd 
Cellulose acetate phthalate Fluka analytical 
Magnesium stearate SD Fine chemicals Ltd, Mumbai. 
 
Table 26:  Equipments used for tablet formulation 
Name of equipment Name of company 
Tablet punching machine  Rimek Mini Press 1 
Tablet disintegration test apparatus   Remi equipments  
Pfizer tablet hardness tester  Scientific engineering corporation  
Roche friability tester  Remi equipments 
Dissolution apparatus Labindia Disso 2000                         
UV spectrometer Jasco V 530 
pH tester 1 (water proof) Oakton instruments. 
 
Method 
 The required amount of drug and the other additives were mixed 
thoroughly in a mortar and the tablets are prepared by direct compression 
using Rimek Mini Press 1 punching machine. The prepared tablets were 
stored in screw capped glass bottles. The prepared tablets were evaluated 
for various quality control and compatibility studies. 
 
EVALUATION OF ORODISPERSIBLE TABLETS 
 The formulated tablets were subjected for the following compatibility 
studies and quality control tests.  
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Compatibility studies 
¾ FTIR compatibility study 
¾ TLC study 
 
Quality control tests 
¾ Thickness and diameter 
¾ Weight variation  
¾ Disintegration test 
¾ Friability 
¾ Hardness 
¾ Drug content uniformity 
¾ Dissolution  
¾ Stability studies 
 
FTIR compatibility study 
 Fourier Transform (FTIR) spectra of formulated ODT was obtained 
in the range of 400-4000 cm-1 using a Jasco-FT-IR 8201 PC 
Spectrophotometer (Jasco.Essex) by the KBr disc method. The IR Spectra 
obtained was given in Figure 28. 
 
Figure 28: FTIR spectrum of formulated Domperidone ODT (F1) 
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Thin layer chromatography 
 Thin layer chromatographic method was carried out to study the 
interaction between the drug and carriers and to confirm the stability of the 
ODTs prepared. For this, the pure drug and the formulations (F1, F4 and 
F7) were subjected to chromatographic studies. Chromatograms were 
generated using precoated TLC plates as stationary phase and methanol: 
dioxin: ammonium acetate solution (40:40:20 %v/v) as mobile phase. The 
Rf values obtained were given in Table 27, the chromatograms were given 
in Figure 29. 
Table 27: TLC data for various formulated ODTs 
S.No Formulation Rf value No of spots 
1 Pure drug 0.70 single 
2 F1 0.71 single 
3 F4 0.71 single 
4 F7 0.70 single 
 
                          
      Pure Domperidone         ODT Formulations 
  
Figure 29: Thin layer chromatogram of drug and formulated ODTs  
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Thickness and diameter 
 Uniform compression force and volume of die fill, leads to uniform 
thickness. From each batch three ODTs were taken and checked with 
vernier, the mean of three tablets and standard deviation were calculated 
and the results were given in the Table 29. Similarly three tablets were 
taken and checked for diameter using vernier, the results were given in 
Table 29.  
  
Weight variation test 
 Twenty tablets were taken weighed individually as per BP. They 
were evaluated for the weight variations. The weight variation allowed as 
per BP limit is 7.5%. The weight of individual tablets were within the BP 
limits. The results were shown in Table 28. 
 
Pharmaceutical form Average mass % Deviation 
≤ 80 mg ± 10 
>  80 mg  <250 mg ± 7.5 
 
Tablets 
≥ 250 mg ± 5 
 
% Deviation = 100  X
 weightAverage
 weightindividual- weightaverage  
Table No. 28: Weight variation of formulated Domperidone ODTs 
S.No Formulation code 
Weight range of 
20 ODTs 
Average 
weight 
Limit range 
(±7.5%) 
1 MS 185-211 198.41 183.53-213.29 
2 F1 198-212 208.36 192.76-223.96 
3 F2 183-208 195.21 180.57-209.85 
4 F3 186-215 197.48 182.66-212.29 
5 F4 197-225 209.47 193.76-225.18 
6 F5 188-214 201.63 186.51-216.75 
7 F6 184-210 198.42 183.54-213.30 
8 F7 194-217 203.91 188.62-219.20 
9 F8 188-207 196.35 181.63-211.07 
10 F9 189-211 197.49 182.68-212.30 
n = 3,± Sd 
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Disintegration test  
 The USP device to test disintegration uses six glass tubes that are 
three inches long open at the top and held against 10 inch screen at the 
basket rack assembly. A tablet is placed in each tube and the basket is 
positioned in a 1 liter beaker of distilled water at 37±2°C, such that the 
tablets below the surface of the liquid on their movement and descend not 
closer than 2.5 cm from the bottom of the tester. The results were shown 
in Table 29 and Figure 30. 
 
Friability test 
 Friability test was performed on the formulated tablets. The weight 
of the tablets after undergoing 100 revolutions was found to be within the 
limits 0.5 to 1.0%. The results were shown in Table 29. 
 
Hardness  
 Pfizer hardness tester was used for measuring the hardness of 
formulated Domperidone ODTs. Five tablets wee taken randomly and 
subjected to test. The hardness was found to be 4-5.4 kg/cm2. The results 
were shown in Table 29. 
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Table No 29: Hardness, friability, and disintegration time of 
formulated Domperidone ODTs and marketed sample  
S. 
No 
Formulation 
code 
Thickness 
(mm) 
Diameter 
(mm) 
Hardness 
(Kg/Cm2 ) 
Friability 
(%) 
Disintegration 
time (sec) 
1 F1 3.1±0.2 7.0±0.6 4.2±0.16 0.55 171±2.86 
2 F2 3.0±0.1 7.1±0.8 4.1±0.11 0.62 78±1.21 
3 F3 3.2±0.2 7.2±0.8 4.1±0.13 0.68 73±1.05 
4 F4 3.0±0.2 7.0±0.9 4.3±0.08 0.52 480±3.22 
5 F5 3.0±0.1 7.2±0.5 4.8±0.15 0.55 436±2.66 
6 F6 3.1±0.3 7.0±0.7 4.9±0.12 0.61 321±2.32 
7 F7 3.1±0.2 7.0±0.6 5.4±0.18 0.54 511±2.57 
8 F8 3.1±0.1 7.1±0.9 5.2±0.17 0.57 494±2.54 
9 F9 3.0±0.2 7.1±0.8 5.2±0.12 0.50 487±2.43 
10 MS 3.0±0.3 7.0±0.6 5.4±0.16 0.54 294±1.38 
n = 3, ± Sd. 
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Figure 30: Disintegration time of formulated Domperidone ODTs and 
marketed sample 
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Drug content uniformity 
 The prepared tablets containing Domperidone solid dispersion was 
tested for drug content uniformity. Tablets were dissolved in 100 ml of 0.1 
M HCl in 100 ml volumetric flask which was previously clean and dry. This 
solution after suitable dilution was measured for absorbance at 286 nm in 
a Jasco V530 UV visible spectrophotometer. The results were shown in 
Table 30. 
 
Table No. 30: Drug content uniformity of formulated Domperidone 
ODTs  
Amount of Domperidone per ODT
S.No Formulation code Amount in 
milligram Amount in % 
1 F1 10.07±0.05 100.73±0.05 
2 F2 10.18±0.11 101.82±0.11 
3 F3 9.88±0.08 98.86±0.08 
4 F4 10.48±0.06 104.85±0.06 
5 F5 10.39±0.10 103.91±0.10 
6 F6 10.11±0.06 101.19±0.06 
7 F7 10.27±0.09 102.74±0.09 
8 F8 10.21±0.11 102.17±0.11 
9 F9 10.24±0.06 102.46±0.06 
10 MS 10.15±0.03 101.52±0.03 
n=3, ± Sd. 
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In-vitro Dissolution studies 
 Dissolution of Domperidone from formulated ODTs were studied in 
BP dissolution medium. The formulated tablets containing solid 
dispersions equivalent to 10mg of Domperidone were taken and the 
paddle type stirrer was adjusted to 50 rpm. The temperature was 
maintained at 37±1°C. 5 ml aliquot dissolution media was withdrawn at 
different time intervals and volume withdrawn was replaced with fresh 
quantity of dissolution media. The samples were analyzed for 
Domperidone by measuring absorbance at 286 nm using Jasco UV visible 
spectrometer. 0.1 M HCl was used as blank. The percentage of 
Domperidone dissolved at various time intervals was calculated and 
plotted against time. The results are shown in Table 31-34 and Figure 29-
32.  
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Table 31: Dissolution profile of formulated ODTs of                        
DOM- PEG 4000 (1:1) solid dispersions 
Percentage of Domperidone release in 0.1 M HCl 
Time in 
minutes Marketed 
sample (MS) F1 F2 F3 
0 0 0 0 0 
5 42.77±1.80 66.15±1.84 82.74±0.92 80.27±0.54 
15 83.94±1.52 84.32±1.19 92.77±0.94 92.42±1.32 
30 86.51±1.48 86.54±1.12 93.06±1.13 92.53±1.47 
45 87.91±1.69 90.41±0.98 94.25±1.25 93.44±1.65 
60 88.62±1.37 91.36±1.04 94.89±1.08 95.66±1.55 
n=3, ± Sd 
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Figure 31: Dissolution profile of formulated ODTs of DOM- PEG 4000 
(1:1) solid dispersions 
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Table 32: Dissolution profile of formulated ODTs of DOM- PEG 4000 
(1:3) solid dispersions 
Percentage of Domperidone release in 0.1 M HCl 
Time in 
minutes Marketed 
sample (MS) F4 F5 F6 
0 0 0 0 0 
5 42.77±1.80 50.94±1.09 33.27±0.98 52.85±2.12 
15 83.94±1.52 93.27±1.16 81.47±1.01 95.77±1.05 
30 86.51±1.48 96.05±1.75 98.27±1.54 96.05±1.16 
45 87.91±1.69 97.03±0.80 98.34±1.14 97.67±1.75 
60 88.62±1.37 99.22±1.01 99.39±1.55 98.20±0.85 
n=3, ± Sd 
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Figure 32: Dissolution profile of formulated ODTs of DOM- PEG 4000 
(1:3) solid dispersions  
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Table 33: Dissolution profile of formulated ODTs of DOM- PEG 4000 
(1:9) solid dispersions 
Percentage of Domperidone release in 0.1 M HCl 
Time in 
minutes Marketed 
sample (MS)
F7 F8 F9 
0 0 0 0 0 
5 42.77±1.80 29.18±0.61 29.71±2.14 27.42±2.13 
15 83.94±1.52 83.02±10.2 78.37±1.35 74.04±1.63 
30 86.51±1.48 98.20±1.07 91.29±1.79 88.69±1.51 
45 87.91±1.69 101.26±1.82 93.30±0.83 90.20±0.78 
60 88.62±1.37 101.29±0.89 93.65±1.36 92.39±0.57 
n=3, ± Sd 
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Figure 33: Dissolution profile of formulated ODTs of DOM- PEG 4000 
(1:9) solid dispersions 
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Table 34: Dissolution profile of formulated Domperidone ODTs and 
marketed sample 
Percentage of Domperidone released from 
Time in 
minutes F1 F2 F3 F4 F5 F6 F7 F8 F9 Marketed sample 
0 0 0 0 0 0 0 0 0 0 0 
5 66.15 82.74 80.27 50.94 33.27 52.85 29.18 29.71 27.42 42.77 
15 84.32 92.77 92.42 93.27 81.47 95.77 83.02 78.37 74.04 83.94 
30 86.54 93.06 92.53 96.05 98.27 96.05 98.20 91.29 88.69 86.51 
45 90.41 94.25 93.44 97.03 98.34 97.67 101.26 93.30 90.20 87.91 
60 91.36 94.89 95.66 99.22 99.39 98.20 101.29 93.65 92.39 88.62 
n=3, ± Sd 
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Figure 34:  Dissolution profile of formulated Domperidone ODTs and 
marketed sample 
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Stability studies  
 The purpose of stability testing is to investigate how the quality of a 
drug product changes with time under the influence of environmental 
factors such as temperature, humidity and light and to establish a shelf life 
for the product and to recommend storage conditions. The guidelines 
promulgated by the international conference on Hormonisation (ICH) are 
the most commonly accepted one for the stability studies. 
 Among all formulated  ODTs, formulation F3 was selected for the 
real time stability study based on its disintegration and dissolution rate 
profile in 0.1 M HCl, and it was kept in the real time stability chamber  
( 30o C and 70% RH) for stability studies. After specified period of time, the 
samples were collected and evaluated for hardness, friability, 
disintegration time and percentage of drug release. The results were given 
in the Table 35 -36 and Figure 35. 
 
Table 35: Physical parameters of stability formulation (F3) in real time 
stability study 
Real time stability 
study 
S.No Parameters 
Initial/zero 
Month 1’st 
month 
2’nd 
month 
1 Hardness (kg/cm2 ) 4.1±0.13 4.1±0.10 4.1±0.12 
2 Friability (%w/w) 0.68 0.67 0.66 
3 Disintegration time (sec) 73±1.05 72±1.2 72±1.0 
n=3, ± Sd 
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Table 36: Dissolution profile of stability formulation (F3) in real time 
stability study 
% of drug release 
Time in mins Initial/zero 
month 
1’st month 2’nd month 
0 0 0 0 
5 80.27±0.54 78.85±0.82 77.22±1.84 
15 92.42±1.32 90.10±1.74 88.68±1.19 
30 92.53±1.47 91.56±1.44 90.78±1.11 
45 93.44±1.65 92.06±1.30 91.64±0.98 
60 95.66±1.55 95.12±1.16 95.08±1.04 
n=3, ± Sd 
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 Figure 35: Dissolution profile of stability formulation (F3) in real time 
stability study 
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MARKETING STRATEGY 
 The total market share of Domperidone tablets, according to the  
Ac-Nielson ORG -2008 data was about 39.5 crore. This market can be 
further expanded by introducing brand extensions catering to the need of 
the prescriber and the patient. The prepared ODTs address the issues of 
poor oral bioavailability of Domperidone and offer a pleasant mouth feel 
dispersible dosage form to improve the patient compliance especially 
geriatric and pediatric patients undergoing treatment for chemotherapy 
induced nausea and vomiting. 
 
Strategic target customers 
 The marketing strategy is primarily targeted to the following 
customers 
¾ Prescribers of immediate release Domperidone tablets. 
¾ Prescribers of metoclopramide. 
¾ Oncologists who treat CINV. 
¾ Pediatricians who practice pediatric oncology. 
¾ General prescribers treating nausea and vomiting. 
Proposed promotional strategy 
¾ To highlight the superiority of ODTs containing SDs in improving 
 oral bioavailability in comparision to immediate release tablets. 
¾ The advantage of Domperidone over Metoclopramide in terms of 
 CNS side effects, as DOM does not cause significant CNS side 
 effects. 
¾ To highlight the use of DOM in CINV for geriatric and pediatric 
 patients. 
¾ To highlight the NSMAS and disintegration time and pleasant mouth 
 feel for better patient compliance.  
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RESULTS AND DISCUSSION 
 An attempt was made to formulate Domperidone Orodispersible 
tablets containing Domperidone solid dispersion with hydrophilic polymer 
PEG to improve oral bioavailability, patient compliance and markettability.  
Nine batches of Domperidone ODTs were prepared using DOM-PEG 4000 
SDs (1:1, 1:3 and 1:9) with croscarmellose sodium in the concentration 
2%, 4% and 8% respectively by direct compression method. Directly 
compressible mannitol, talc, magnesium stearate and Non sugar 
mucoadhesive sweetener (NSMAS) made with aspartame were used as a 
excipients for the formulation and the details were shown in Table 24. 
 
Compatibility studies 
 The compatibility between the drug and the excipients were 
evaluated by FTIR matching approach. The IR spectra of F1 showed in 
Figure 28  shown a characteristic absorbance peaks at 3431.71 cm-1, 
1687.41 cm-1 , 1572.66 cm-1, 1461.78 cm-1, 1338.36 cm-1 and 788.74 cm-1 
these frequencies matched with frequencies observed in the IR spectrum  
of pure Domperidone. This confirmed that the absence of any chemical 
interaction between Domperidone and excipients. 
 The TLC data was shown in Figure 29, revealed that the Rf value of 
F1, F4 and F7 were matching with that of pure DOM and no additional 
spots were seen. This suggested that there were no interaction between 
the drug and the excipients. 
 
Physical characterization 
 The diameter, thickness and friability of all formulated ODTs were 
given in Table 29. Hardness was found to be in the range of 4.1±0.11 to 
5.4±0.18, and was satisfactory. The percentage weight loss in the friability 
test was found to be between 0.50 % to 0.68 % and was less than 1% in 
all formulations indicated that tablets had good mechanical resistance. 
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Weight variation and Drug content uniformity 
  To be acceptable by USP standards, the weight variation tolerance 
for uncoated tablets must be 7.5% or less. As the tablet powder mixture 
was free flowing, tablets produced were of uniform weight with acceptable 
weight variation due to uniform die fill .All the ODTs prepared were found 
to contain the medicament within 102.1± 1.65 % of label claim. All the 
formulated ODTs (F1-F9) employing super disintegrant Croscarmellose 
sodium were found to be good quality fulfilling the official requirements of 
compressed tablets for weight variation and content uniformity, Table 28  
and 30. 
 
Disintegraton test   
 The disintegration profile was given in Table 29 and Figure 30 
showed among all formulations F1, F2 and F3 ODTs disintegrated within  
3 minutess, and fulfilling the BP requirement for ODTs. Formulation F3 
containing 8% of croscarmellose sodium had faster disintegration time 
than F1 and F2 (2% and 4% respectively). The disintegration time of 
formulations F1, F2 and F3 were faster than the marketed sample of 
immediate release conventional tablet . 
 In ODTs of SDs containing 50 % (F1, F2 and F3) and 75% (F3, F4 
and F6) of PEG 4000, as the concentration of croscarmellose sodium 
increases disintegration time decreases exponentially. But ODTs of SDs 
containing 90% of PEG 4000(F7, F8 and F9) the disinegration time was 
almost similar (511 ±2.5 sec, 494±2.5 sec and 487±2.4 sec) as the 
concentration of croscarmellose sodium increased. The increased 
disintegration time of tablets may be due to large amount of PEG 4000. 
When there was a large amount of PEG 4000, its binding properties were 
stronger than the swelling and disintegrating effect of croscarmellose 
sodium, slowing disintegration time. 
 In contrast, when there was a small amount of PEG 4000 (F1, F2 
and F3) the effect of croscarmellose sodium was more pronounced, 
allowing faster disintegration. The order of disintegration was found to be 
F3 < F2 < F1 < MS< F6 < F5 < F4 < F9 < F8 < F7. 
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Dissolution studies 
  The dissolution profile of formulated ODTs and conventional 
marketed formulation were shown in Table 31 - 34. Tablets formulated 
with solid dispersions gave rapid dissolution of the medicament when 
compared to that of marketed sample. The dissolution of medicament from 
all tablets followed first order kinetics. The percentage release of all 
formulations (F1-F9) was between 90 and 101 % at 45 min when 
compared with the marketed sample which had around 89% release.T90  
was less than 15 min for formulations F2,F3,F4 and F6, but for marketed 
sample t90 is more than 60 minutes. This shows faster release of drug from 
ODTs when compared to market sample. The faster and increased rate of 
release may be due to the rapid disintegration and increased wetability 
because of the hydrophilic polymer. 
 The order of dissolution of Domperidone from various ODT 
formulations was F7 >  F5   >   F4  >  F6   >  F3   >   F2  >  F8  >  F9  >  F1 
> MS . 
Stability studies 
 Data for stability studies were given in Table 35 and 36 shown that 
the stability studies performed for F3 at temperature 30o C and relative 
humidity of 70 % revealed that no considerable changes were observed in 
drug content during 2 months. 
Marketing strategy 
 Based on the market potential of Domperidone ODTs , the strategy 
focused on the merits of Domperidone over Metoclopramide in treating 
nausea and vomiting, the advantage of ODTs over immediate release 
tablets in terms of compliance, the advantage of improved bioavailability 
due to the formulation containing solid dispersion of Domperidone and 
also its release in the oropharangeal region which by pass hepatic  first 
pass effect. 
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SUMMARY AND CONCLUSION 
 Studies were under taken on the formulation and evaluation of 
Orodispersible tablets of Domperidone from selected solid dispersions with 
hydrophilic polymer PEG with a view to improve dissolution as well as oral 
bioavailability, patient compliance marketability characteristics of 
Domperidone. Three grades of polyethylene glycols viz PEG 4000, PEG 
6000 and PEG 8000 were used to prepare the SDs of Domperidone by 
solvent evaporation method at various drugs: carrier ratios namely (1:1, 
1:3 and 1:9). The SDs prepared was found to be fine and free flowing 
powders.  
Interaction studies such as TLC, FTIR revealed no interaction 
between drug and polymer PEG. 
 X-ray diffraction studies revealed that crystalline nature of 
Domperidone in pure form was reduced to amorphous form in the 
dispersions. The thermal behavior of Domperidone-PEG SDs (1:1, 1:3 and 
1:9) was studied using DSC showed shifting of endothermic peaks of 
Domperidone to lower melting point, indicating transition of low energy 
crystalline nature of Domperidone in pure form to a higher energy 
amorphous state. Endothermic peaks pertaining to the polymer has not 
shown any change, this revealed that DOM has completely homogenously 
dispersed in the polymer and shown no interaction.  
The SEM of pure drug and the solid dispersion revealed that the 
changes in the morphological characteristics of pure Domperidone from 
crystalline nature to amorphous nature in the solid dispersion. 
 Results of dissolution studies showed rapid and fast dissolution of 
Domperidone from all solid dispersions when compared with the pure drug 
and physical mixture. Good correlation was observed between percentage 
carrier in the solid dispersion and T50 and T90 values. The higher 
dissolution rate was observed with drug: carrier ratio of 1:9. SDs of PEG 
4000 at 1:1, 1:3 and 1:9 gave more than 90 % release at 45 min.  
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 The order of dissolution of Domperidone from various carriers is 
DOM-PEG 8000(1:9) > DOM-PEG 6000(1:9) > DOM-PEG 4000(1:9) > 
DOM-PEG 6000(1:3) > DOM-PEG 4000(1:1) > DOM-PEG 4000(1:3) > 
DOM-PEG 8000(1:3), DOM-PEG 8000(1:1) > DOM-PEG 6000(1:1) > pure 
drug. 
 Domperidone solid dispersion in PEG 4000 (1; 1, 1:3 and 1:9) was 
formulated into tablets with superdisintegrant croscarmellose sodium in 
(2%,4% and 8%), directly compressible mannitol as diluents and non 
sugar mucoadhesive sweetener and other additives. 
 Compatibility studies by FTIR and TLC revealed absence of any 
chemical interaction between Domperidone and excipients. 
 Quality control tests such as friability, hardness weight variation and 
content uniformity showed all ODTs fulfilled the official requirement of 
compressed tablets. 
 ODTs prepared with DOM- PEG 4000(1:1), F1,F2 and F3 showed 
disintegration time less than 3 min when compared with the marketed 
sample which took almost 5 minutes and also fulfilled BP requirement for 
ODTs. Other formulations (F4, F5, F6, F7, F8 and F9) showed DT more 
than 3 min and were not fulfilled the requirements, thus cannot be 
considered as ODTs.  
 The dissolution of Domperidone from ODTs was found to be fast 
and rapid when compared with marketed sample. The additives added 
have not hindered the dissolution of Domperidone from SDs. All ODT 
formulations based on the solid dispersion fulfilled the official dissolution 
requirements. The stability studies revealed that there were no 
considerable differences in drug content and dissolution profile over a 
period of two months. 
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Since it can be concluded that formulations F1,F2 and F3 were 
formulated using DOM-PEG 4000 (1:1) with superdisintegrant 
croscarmellose sodium in 2%,4% and 8% respectively, were adhere to the 
BP requirements in terms of disintegration time and dissolution profile to 
be considered as Orodispersible Tablets of Domperidone.   
As other formulations namely F4, F5, F6, F7, F8, and F9 were 
shown disintegration time more than 3 minutes thus cannot be considered 
as Orodispersible tablets as per BP requirements.  
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 Abbreviation 
ABBREVIATIONS 
 
 
AP   - Area postrema 
BCS   - Biopharmaceutical classification of drugs 
BP   - British pharmacopoeia 
CINV   - Cytotoxic induced nausea and vomiting 
CTZ   - Chemoreceptor trigger zone 
DMF   - Dimethyl formamide 
DOM    - Domperidone 
DSC   - Differential Scanning Calorimetry 
DT   - Disintegration time 
IR   - Infra Red 
MS   - Marketed sample 
NSMAS  - non sugar mucco adhesive sweetener 
ODT   - Orodispersible tablet 
PEG   - Polyethylene glycol 
PM   - Physical Mixture 
SD    - Solid Dispersion 
Sd   - standard deviation  
SEM   - Scanning electron microscopy 
TLC   - Thin Layer Chromatography 
USP   - United States Pharmacopoeia 
